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SUMMARY 
HIV and AIDS have drastically compromised the quality of life and lifespan for 
millions of people worldwide. The increasing effectiveness of and access to antiretroviral 
therapy has dramatically increased the life expectancy of those infected with HIV to nearly 
that of the general population. Once considered a death sentence, a positive HIV diagnosis 
with appropriate treatment is now a chronic condition bringing with it the premature onset 
of disorders traditionally associated with the natural aging process including cardiovascular 
disease, neurocognitive decline, kidney disease, and osteoporosis. It is well understood that 
HIV infection is a risk factor for osteopenia and osteoporosis and subsequently for fragility 
fractures. More recently, studies have established an increase in fracture prevalence in the 
HIV-infected population. However, the effects of HIV infection on bone are difficult to 
investigate in the clinical setting. Traditional risk factors for osteoporosis – such as vitamin 
D deficiency, drug use, smoking, and alcohol use – can complicate any observed effects 
that HIV may have. Despite the increased risk for fracture and fracture prevalence in the 
HIV-infected population, relatively few clinical studies and no pre-clinical studies have 
investigated the potential for HIV infection to adversely affect fracture healing. 
The main goal of this work was to investigate the effects of HIV on skeletal growth 
and bone healing as exhibited by HIV-1 transgenic rodent models, specifically the mouse 
and the rat. In addition to the extensive body of bone research conducted in mouse and rat 
models, the transgenic rodent models offer significant advantages for pre-clinical research 
over the more recognized non-human primate and humanized mouse models, including 
less time and expense. Additionally, HIV-1 transgenic rodent models have been used to 
 xvii 
study various comorbidities associated with HIV infection. Thus, we first characterized the 
skeletal phenotype in the HIV-1 transgenic mouse model by evaluating bone 
microarchitecture and biomechanics. We further assessed whether HIV mice present with 
impairment in long bone fracture healing. Second, we characterized the longitudinal 
skeletal changes in the growing HIV-1 transgenic rat. Finally, we investigated alterations 
to bone healing in the HIV-1 transgenic rat using a critically-sized segmental bone defect 
model.  
This work presents findings supporting an HIV associated skeletal phenotype that 
is exhibited by both HIV-1 transgenic mice and rats that reflects the clinical literature. 
Specifically, HIV animals have reduced cortical and trabecular bone mass and altered bone 
microarchitecture at multiple skeletal sites. These deleterious effects on bone structure 
resulted in decreased whole bone mechanics and may be age-dependent in HIV-1 
transgenic rodents. More significantly, we present the first pre-clinical investigation into 
fracture healing in the HIV-1 transgenic rodents showing impaired bone healing in both 
HIV-1 transgenic mice and rats. Our findings support the clinical need to monitor skeletal 
health in the HIV infected population and further emphasize the unmet need for robust 








CHAPTER 1. SPECIFIC AIMS 
1.1 Introduction 
An estimated 36.7 million people worldwide are infected with the human 
immunodeficiency virus (HIV) and 1.8 million people were newly infected in 2016 [1]. 
Without treatment, HIV infection typically progresses to end-stage acquired immune 
deficiency syndrome (AIDS) and eventually death. The effective administration of 
antiretroviral therapy (ART) has drastically improved the life expectancy of the HIV 
infected population [2, 3]. Once considered a death sentence, a positive HIV diagnosis with 
appropriate treatment is now a chronic condition bringing with it the premature onset of 
disorders traditionally associated with the natural aging process including cardiovascular 
disease, renal (kidney) disease, hepatic (liver) disease, neurocognitive decline, and bone 
disorders [4-7]. 
It is commonly recognized that HIV infection is associated with low bone mineral 
density (BMD) and consequent risk for osteoporosis and fragility fractures [8]. In recent 
years, it has been shown that the prevalence of fracture with HIV infection is also increased, 
further emphasizing HIV’s negative effect on skeletal health [9, 10]. However, the effects 
of HIV infection on bone are difficult to investigate in the clinical setting and to-date poorly 
understood [11]. Additionally, there is a paucity of robust studies investigating the potential 
adverse effects of HIV on bone repair despite the increased risk for and prevalence of 
fracture [12, 13]. 
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The most commonly used animal models in HIV/AIDS research – non-human 
primates, humanized mice, and felines – have been utilized heavily in the search for a cure 
[14]. These models, while more applicable to HIV cure research, are disadvantaged for 
investigations into non-AIDS-related comorbidities by the considerably more resource 
intensive nature of the animal models as well as the inherent risk in using active viral 
infection specifically with humanized mice [15]. In contrast, the HIV-1 transgenic (tg) 
mouse and rat are noninfectious and colonies are easily maintained [16, 17]. Both have 
also been used in studies on the various HIV-associated comorbidities [16-24]. 
Additionally, laboratory mouse and rat models have been used extensively in both 
osteoporosis [25] and bone healing research [26, 27]. Considering this information, the 
HIV-1 transgenic rodent models are attractive vehicles for examining bone-related 
disorders in the context of HIV as presented by these animals. Therefore, the overall 
objective of this work was to investigate the effects of HIV on skeletal growth and bone 
healing as exhibited by two noninfectious HIV-1 transgenic rodent models, specifically the 
mouse and the rat. The central hypothesis of this project was that HIV-1 transgenic animals 
will present with significant deficiencies in skeletal development and bone repair. We 
tested this hypothesis via the following three aims: 
1.2 Aim I 
Characterize the skeletal phenotype and fracture healing of the HIV-1 transgenic 
mouse. 
Despite the evidence for use of HIV-1 tg mice in the study of select HIV-associated 
comorbidities, there are very few research studies using the models for bone-relevant 
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research. The opportunity to utilize one of these noninfectious models to investigate bone 
abnormalities was generously provided by Dr. Rudy Gleason and Dr. Roy Sutliff as a part 
of their ongoing research studies. Thus, the goals of this aim were to characterize the 
structural and biomechanical phenotype of HIV-1 tg mouse bone and to investigate fracture 
healing differences between HIV and control (WT) mice. First, to test the hypothesis that 
HIV mice would have impaired bone structure and function compared to WT mice, we 
analyzed the femur and L6 vertebra using microcomputed tomography (microCT) for bone 
microarchitecture and mechanical testing procedures to determine effects on 
biomechanical properties. Second, to test the hypothesis that HIV mice would have 
impaired bone healing, we implemented a closed femur fracture model using 
intramedullary stabilization to compare the fracture healing response in HIV-1 tg and WT 
mice. 
1.3 Aim II 
Investigate the longitudinal skeletal phenotype in the growing HIV-1 transgenic rat. 
The noninfectious HIV-1 provirus used to generate the HIV-1 tg mouse from Aim 
I is the same used to create the HIV-1 tg rat. However, significant differences exist between 
the two species including more efficient HIV gene expression in the rat resulting in the 
presence of viral proteins in multiple lymphatic tissues. Although one study in the literature 
established that male HIV-1 tg rats present with an osteoporotic phenotype starting at 8-9 
months of age, no studies have shown skeletal changes over time or bone biomechanics in 
this model. Therefore, the goal of this aim is to characterize the changes to the skeleton in 
the growing HIV-1 tg rat and the subsequent aged bone biomechanical properties at the 
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end of the study. Changes in cortical and trabecular bone architecture were assessed using 
microcomputed tomography (microCT). Serum levels of bone turnover markers were 
assessed for global changes in bone remodeling. Finally, bone biomechanical properties 
were determined for femurs and vertebrae. We hypothesized that alterations to bone 
morphology and function would occur in the 5- to 9-month period of HIV/AIDS 
symptomatic onset leading to an osteoporotic phenotype and impaired biomechanics in 
HIV-1 tg animals. 
1.4 Aim III 
Evaluate bone healing in the HIV-1 transgenic rat using a long bone segmental defect 
repair model. 
Much of the clinical investigations into fracture healing in the HIV infected 
population have looked at closed and open fractures with a special interest in wound 
infection and clinical management. However, no clinical or preclinical studies have looked 
at the significant challenge that large bone defects may pose in the HIV infected population. 
The results from Aim I and Aim II provide support for the hypothesis that bone healing in 
HIV-1 tg rats would be impaired. Thus, the objective of this aim was to investigate whether 
the HIV condition of the HIV-1 tg rat influences BMP-2 mediated segmental bone defect 
repair using a well-established rat femur segmental bone defect procedure. A critically 
sized 8 mm mid-femoral bone defect was used in conjunction with a biomaterials-based 
therapeutic utilizing BMP-2 to induce bone healing. The bone healing process was assessed 
using qualitative x-ray radiographs and quantitative microCT scans. Functional restoration 
was evaluated via ex vivo biomechanics. We hypothesized that repair of the critically-sized 
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large bone defect would be impaired in the HIV-1 transgenic rats despite therapeutic 
intervention.  
1.5 Significance and Scientific Impact 
Millions of people continue to live with HIV infection, and although significant 
improvements to life expectancy and quality of life have been achieved, this growing and 
aging population is faced with many new challenges including greater risks for 
osteoporosis and fractures. While considerable progress has been made towards elucidating 
the connections between HIV and bone, there is yet more work to do to unravel this 
complex relationship. The use of animal models for HIV/AIDS research is especially 
difficult given that HIV is a human-specific virus and the current state-of-the-art in animal 
models for cure research are resource intensive. However, in addition to the extensive body 
of bone research utilizing both mice and rats, the HIV-1 transgenic rodent models are 
noninfectious and require less expertise and resources. Additionally, these models have 
been shown to be useful for researching HIV-associated comorbidities including 
cardiovascular disease, renal dysfunction, and neurocognitive decline. There remains a 
continued need for a useful small animal model to study bone disorders with HIV. 
The work put forth here is significant because it has characterized the skeletal 
phenotype and bone healing response in the HIV-1 tg mouse and rat models in order to 
validate them for use in further research into the alterations to normal skeletal structure and 
function. This adds to the body of work investigating the clinically relevant HIV-associated 
comorbidities manifested in the HIV-1 tg rodent models. Additionally, it presents the first 
pre-clinical research on the effects of HIV-1 on bone healing as exhibited in the HIV-1 tg 
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rodent models. Specifically, this project has shown both rodent models exhibit a skeletal 
phenotype characterized by negatively altered bone microarchitecture and bone mechanics 
that agrees with clinical findings in HIV infected individuals. More importantly, the HIV-
1 tg mouse and rat models both present with impairment of the normal bone healing process 
emphasizing the need for further clinical attention to fracture management in the HIV 
positive patient, especially with older patients.  
Animal models are inherently disadvantaged when it comes to translating findings 
to the human condition. However, the opportunities they provide towards increasing 
understanding of disease mechanism and the significant impact on quality of life in humans 
is not trivial. As the HIV infected population continues to grow and to age, the once 
considered homogeneous demographic has become a far more epidemiologically diverse 
population of concern that will require a similarly diverse body of research. By presenting 
the HIV-1 tg rodent models as functional surrogates for orthopedic and HIV research, this 
work has provided the ground work for further exploration of the association between HIV 
and bone disorders. 
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CHAPTER 2. BACKGROUND 
2.1 Bone Physiology 
2.1.1 Bone Structure and Function 
Bone is a fascinatingly complex and critical organ of our bodies. As the 
fundamental component of the skeletal system, bone serves multiple metabolic and 
structural roles including a repository of calcium and phosphate for mineral metabolism; 
supporting hematopoiesis in the bone marrow; protecting internal organs; and providing a 
rigid yet flexible structure for stability and movement. Commonly perceived as a static 
material, bone is dynamic in nature, constantly adapting to changes in its mechanical and 
physiological environment. It develops into specialized shapes and sizes during rapid 
growth and repairs itself to optimize mechanics and prevent catastrophic failure [28].  
Bone can be divided into two types: cortical (compact) and trabecular (cancellous). 
These bone types are present in varying ratios throughout the skeleton providing different 
degrees of mechanical support. Cortical bone is dense with very low porosity and makes 
up approximately 80% of the adult human skeleton [29]. Primarily found in the diaphysis 
of long bones like the femur, cortical bone is present as the outer wall of all bones. 
Trabecular bone makes up the remaining 20% of the human skeleton and can be found in 
the epiphysis and metaphysis of long bones and in the inner compartment of vertebrae. It 
is characterized by a highly interconnected network of trabecular structures called plates 
and rods. Macroscopically, the highly porous trabecular structure provides considerable 
shock absorption and facilitates load transfer to cortical bone [28, 30]. Cortical bone, on 
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the other hand, is stiffer and can support greater ultimate stresses than trabecular bone but 
is more brittle [31]. 
The unique mechanical contributions of cortical and trabecular bone can be 
highlighted by comparing bones from different skeletal sites, specifically the femur and the 
vertebra. In the femur, the ratios of cortical and trabecular bone range from no trabecular 
bone at the mid-diaphysis to predominantly trabecular bone at the femoral head-neck 
junction [28, 31]. Here, cortical bone provides significant support under shear forces and 
bending moments and the trabecular bone contributes considerably less to the mechanical 
integrity of the femur. In the vertebra, the trabecular compartment provides the bulk of the 
mechanical strength supporting the predominantly compressive loads seen in the spine. 
Irrespective of the bone type, bone is composed primarily of inorganic mineral 
(~65%) and organic protein (~25%) elements with the organic components made up 
primarily of type I collagen (90%) [32]. The mineral phase of bone consists mainly of a 
nanocrystalline called hydroxyapatite [Ca10(PO4)6(OH)2] whose greater solubility 
compared to geologic hydroxyapatite crystals allows support of mineral metabolism [29]. 
While the mineral side provides the stiffness of bone and the organic side imparts ductility, 
it is the combination of the two in varying amounts and arrangements that dictate the 
mechanical properties of bone from the nanoscale to the whole bone. 
Bone is able to adapt to changes in stresses and strains through the processes of 
modelling and remodelling thereby adjusting bone composition and morphology [28]. 
Modelling is characterized by an activation signal followed by either resorption or 
formation of bone at a particular location [33]. This process seeks to optimize the shape of 
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the bone in response to the rapid growth towards adulthood. Unlike modelling, remodelling 
is a tightly regulated sequential progression of activation, resorption, and formation that 
replaces a specific volume of bone. There are three bone cell types involved in these 
processes: osteoblasts, osteocytes, and osteoclasts. Osteoblasts are the bone forming cells 
that derive from mesenchymal progenitors. As osteoblasts lay down new bone matrix, 
some of them remain behind and eventually become embedded in the bone tissue to 
differentiate into osteocytes. Osteocytes are the most common bone cell type and play a 
critical role in sensing mechanical strain and microdamage. Osteoclasts are the bone 
resorbing cells of the monocyte-macrophage lineage recruited from the bone marrow or 
potentially from circulation. Together, the osteocytes, osteoblasts, and osteoclasts work in 
concert to maintain healthy and functional bone tissue. 
2.1.2 Bone Development and Healing 
Skeletal development and growth follows two distinct processes known as 
endochondral and intramembranous ossification [34, 35]. Development and growth of long 
bones occurs through endochondral ossification and is characterized by the formation and 
subsequent replacement of cartilage with bone tissue. Proliferating chondrocytes 
differentiate into hypertrophic chondrocytes which initiates the process of cartilage 
resorption by osteoclasts, bone deposition by osteoblasts, and blood vessel formation. In 
flat bones such as in the skull, intramembranous ossification occurs when 
osteochondroprogenitor cells differentiate into osteoblasts which subsequently lay down 
bone matrix, bypassing the cartilage phase present in endochondral ossification. The newly 
formed bone from either process is characterized by a disorganized arrangement of 
collagen fibers and is referred to as primary, immature, or woven bone [32]. This bone is a 
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placeholder, formed rapidly to provide temporary stability and structure to the surrounding 
tissues. It is quickly remodelled and replaced by lamellar (also secondary or mature) bone, 
a more mechanically competent mineralized tissue with highly organized collagen fibers. 
Bone is unique in its ability to heal without scar tissue through a process combining 
endochondral and intramembranous ossification [36]. Bone healing can be categorized into 
primary (direct) and secondary (indirect) healing. Primary fracture healing is not common 
and requires strict stability of the injury site with little to no gap between fractured bone 
ends. Secondary fracture healing is the most common path towards bone healing and does 
not require strict stable fixation or contact between fractured bone ends. In fact, some 
degree of instability and micromotion is necessary for proper bone healing. The fracture 
healing cascade follows a continuum of processes starting with the bone injury and 
progressing to formation of a hematoma, an inflammatory phase, soft callus formation, 
transition to hard callus, and remodelling phase.  
Bone injury causes significant damage to the vasculature in and around the bone 
resulting in an influx of blood and the formation of a hematoma [37]. The subsequent acute 
inflammation involves multiple inflammatory cells including polymorphonuclear 
leukocytes, monocytes, macrophages, T cells, and B cells [38]. This phase clears out debris 
and necrotic tissue, promotes angiogenesis, and initiates recruitment of 
osteochondroprogenitors via a variety of inflammatory and chemotactic cytokines as well 
as key growth factors including bone morphogenetic proteins (BMPs) [37]. As a result of 
the injury, the local environment closest to the central region of the injury site has become 
more hypoxic, avascular, and mechanically unstable than the regions further from the 
fracture site. This fracture site microenvironment encourages chondrogenesis and 
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formation of a cartilaginous soft callus that stabilizes the area and sets the stage for 
endochondral ossification. Concurrently, primary bone healing via intramembranous 
ossification begins some distance away from the soft callus and advances towards the 
region of injury. Subsequently, the soft callus chondrocytes differentiate into hypertrophic 
chondrocytes and eventually undergo apoptosis, leaving behind a calcified cartilage matrix 
and promoting vascular ingrowth. The process of endochondral ossification proceeds as 
the cartilage is resorbed by osteoclasts and primary bone formation by osteoblasts begins 
leading to the formation of a hard callus. This mineralized cartilage and woven bone matrix 
is then remodelled and replaced by lamellar bone which continues to be remodelled until 
the native bone structure and mechanical strength is restored.  
2.2 HIV-1 Pathology 
2.2.1 Virus and Infection 
The human immunodeficiency virus 1 (HIV-1) is a member of genus Lentivirus 
under the family of Retroviridae [39]. The life cycle of HIV-1 can be summarized as 
infection of a cell, integration of viral genome, viral gene expression, and production of 
viral particles [39, 40]. HIV-1 infection of a cell begins with a sophisticated interaction of 
viral surface proteins with host cell surface receptors. Initially, the glycoprotein gp120 on 
the HIV particle surface binds to the CD4 receptor of CD4+ cells which include T helper 
cells, macrophages, dendritic cells, and astrocytes. Subsequent conformational changes 
and binding to co-receptors – chemokine receptor 5 (CCR5) or chemokine receptor 4 
(CXCR4) – results in the fusion of the virus and host cell membrane. The viral contents 
are released into the cytoplasm and the viral RNA is reverse transcribed into DNA which 
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is subsequently transported to the nucleus for random integration into the host cell’s 
genome. Utilizing the host cell’s transcriptional and translational machinery, the HIV genes 
are transcribed into mRNA which is then translated to produce the various viral proteins 
needed for a mature HIV particle. Finally, the virus is assembled, buds, and is released 
from the host cell membrane to mature and infect more cells. The whole process from HIV-
cell attachment to release of new viral particles takes approximately 24 hours [39]. 
The HIV-1 genome consists of nine genes that code for the structural and regulatory 
proteins necessary for HIV-1 replication and infection [39, 40]. Three of these genes – gag, 
pol, and env – are common to all retroviruses while the remaining six are regulatory 
proteins unique to HIV-1. The proteins encoded by gag make up the structure of the viral 
core. The pol gene codes for the major viral enzymes including reverse transcriptase and 
integrase. The surface proteins gp120 and gp41 critical for virus-cell attachment are 
encoded by env. The regulatory proteins Tat, Rev, and Nef are the first produced after 
infection and are essential for accelerating viral gene transcription, facilitating transport 
from the nucleus to the cytoplasm, and reduction of cytoplasmic CD4 levels, respectively. 
The additional accessory proteins Vif, Vpr, and Vpu influence the infectiousness, maturity, 
and production of viral particles.  
As described by the Centers for Disease Control and Prevention (CDC), HIV 
infection progresses through three stages: acute infection (Stage 1), clinical latency (Stage 
2), and AIDS (Stage 3) [41]. Initial HIV infection (Stage 1) results in rapid viral replication 
and, within 2 to 4 weeks, flu-like symptoms that can last anywhere from several days to a 
few weeks [42]. In response to the sharp rise in viremia, HIV-1 specific cytotoxic T cells 
attempt to eliminate the virus from the body, lowering the viral load to what is called a 
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viral load set-point. The actual HIV-1 viral load oscillates about this steady value and can 
vary significantly from individual to individual [43]. This phase of steady viral load 
characterizes the asymptomatic phase (Stage 2) wherein the infected individual may or 
may not present with symptoms, a state that can last up to ten years or more [41]. During 
this time, the viral infection is slowly depleting the body of a functional immune system 
[44]. As stated previously, HIV can infect multiple cell types but the eventual progression 
to AIDS is a consequence of a dramatic loss in CD4+ T cells [45]. These T cells are critical 
to the immune system, modulating other immune cell function and recruitment through the 
secretion of various cytokines and chemokines [46]. A Stage 3 AIDS diagnosis is defined 
by a CD4+ T cell count that is below 200 cells/mm3 or, as a consequence of a compromised 
immune system, the presence of opportunistic illnesses [41]. Individuals with AIDS 
survive around three years without treatment.  
2.2.2 Epidemiology 
The HIV/AIDS epidemic continues to impact the quality of life of millions of 
people worldwide. In 2016, over 36 million people in the world were living with HIV with 
an estimated 2.1 million under the age of 15 [1] and in 2014, 4.2 million over the age of 50 
or about 13% of the adult population living with HIV [47]. In the early 1980s in the United 
States, HIV infection was associated with young, white, men who have sex with men 
(MSM), but this demographic has since diversified across race/ethnicity, gender, and age 
[48]. In fact, the highest prevalence of HIV infection at the end of 2015 by race was among 
blacks/African Americans; by age group was among those 45-54 years old; and by sex was 
among males [49]. Additionally, an estimated 14.5% of those living with HIV over the age 
of 13 years in the United States did not know they were HIV positive. UNAIDS reported 
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that the rate of infections globally is on the decline, but 1.8 million new infections were 
estimated for 2016 [1] with nearly 40,000 people receiving a new HIV diagnosis in the 
United States [50]. 
Early in the HIV/AIDS epidemic, a positive HIV diagnosis was almost certainly a 
death sentence. With the advent of effective treatment initially called highly active 
antiretroviral therapy (HAART) and now simply antiretroviral therapy (ART), patients 
infected with HIV can expect to live considerably longer and to nearly that of the 
uninfected population [3, 51]. Efforts to develop a cure and to prevent new HIV infections 
have been substantial, however neither has yet been successful in removing HIV/AIDS as 
a both an acute and chronic healthcare concern. Consequently, living with HIV infection 
requires a strict adherence to ART regimens which, over a lifetime, can result in adverse 
side effects from ART itself, drug interactions from polypharmacy, drug resistance, or 
significant pill burden [51, 52]. 
2.2.3 HIV-Associated Comorbidities 
Living with HIV has become a chronic condition so long as patients adhere to their 
therapeutic regimen [53]. Unfortunately, longer lifespans have brought with it unexpected 
complications including traditionally age-related comorbidities such as cardiovascular 
disease, renal disease, liver disease, neurocognitive decline, and osteoporosis [4, 51, 54]. 
The onset of these complications has also been suggested to occur at a younger age 
compared to the uninfected population leading to the hypothesis that individuals with 
chronic HIV infection and effective ART have a syndrome of premature aging [55, 56]. 
This syndrome may be a combined consequence of chronic immune activation and latent 
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viral reservoirs, functional HIV that is “hiding” in resting cells [57, 58]. These HIV 
reservoirs may continue to replicate at low levels in part due to low concentrations of 
antiretroviral drugs in various tissues [58]. Additionally, it is suspected that viral proteins 
continue to be produced despite effective therapy as found in the blood and tissues of HIV 
patients on ART [59-62]. 
2.3 HIV and Bone 
2.3.1 Low Bone Mass 
Osteoporosis is the most common bone disease afflicting millions of people in the 
world. It is characterized by significantly low bone mass and poor bone quality and 
consequently an increased risk for fragility fractures such as those that occur from falls [63, 
64]. According to the World Health Organization (WHO) guidelines, if an individual’s 
bone mineral density (BMD) – measured using dual energy x-ray absorptiometry (DXA) 
– falls at or below 2.5 standard deviations from the mean peak BMD of young adults, then 
they are diagnosed as having osteoporosis [65]. Low bone mass has been found to be a 
significant concern in the HIV positive population. In a meta-analytical review, Brown and 
Qaqish found an increased prevalence of reduced BMD and osteoporosis in the HIV 
positive population whether patients were ART-naive (odds ratio, OR, of 6.4 and 3.7, 
respectively) or ART-treated (OR of 2.5 and 2.4, respectively) when compared to 
respective uninfected controls [66]. In a more recent meta-analysis, Goh and colleagues 
found that HIV-infected individuals had a comparatively lower but still significant 2-fold 
increased prevalence of osteopenia/osteoporosis compared to uninfected controls 
regardless of ART treatment status [67]. More specifically, HIV positive men have 
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significantly decreased BMD at the femoral neck and lumbar spine compared to uninfected 
controls with prevalence of osteopenia or osteoporosis in the study cohorts ranging from 
51% to 82% [68-72]. Similarly, lower BMD is more prevalent in women infected with HIV 
with rates of osteopenia or osteoporosis ranging from 23% to 78% [73-78]. Although much 
of this evidence comes from research from resource rich settings, the impact on bone health 
is similarly deleterious if not more so in resource limited settings [79]. Additionally, the 
prevalence of low bone mass afflicts children and adolescents infected with HIV. The risk 
of mother-to-child transmission of HIV is very high without ART, but treatment can reduce 
this risk considerably. However, maternal HIV infection is associated with a higher risk of 
preterm birth, low birth weight, and small-for-gestational-age whether the mother is ART-
naïve or not [80, 81]. Premature birth, low weight at birth, or poor growth early in life may 
lead to below normal peak bone mass and bone strength [82, 83]. Whether infected 
perinatally or behaviorally, multiple studies have shown that HIV infected children and 
adolescents have reduced bone mass [84-86]. In a study of HIV infected males in their 
early 20s, Yin and colleagues showed that early infection results in a subnormal peak bone 
mass [87]. Given that peak bone mass is a critical predictor of osteoporosis and fracture 
risk [88, 89], HIV positive youth may be at a greater risk for skeletal complications later 
in life. Although comparisons between studies can be difficult to make given differences 
in cohort characteristics including sample size, alcohol consumption, smoking, drug use, 
BMI, age, race/ethnicity, and menopausal state, there is significant evidence for a high risk 
of low bone mass in HIV infected individuals regardless of various demographic 
characteristics. 
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In addition to bone mass concerns, skeletal fragility in osteoporosis is a 
consequence of an imbalance in the bone remodelling process whereby bone resorption is 
at a level that bone formation is not matching [90]. How bone remodelling is unbalanced 
in the context of HIV depends on many factors including severity of HIV infection, level 
of immune dysfunction, effects of ART, comorbidities, and behavioural risk factors [91]. 
Much of the research looking at bone turnover in HIV patients is concerned with ART 
effects which can vary by drug. Overall, there is evidence for increased bone turnover in 
HIV positive individuals initiating ART that remains at elevated levels compared to pre-
treatment levels [91-95]. In ART-naïve HIV patients, bone formation appears to be 
suppressed with resorption levels equal to or greater than uninfected controls [78, 96]. 
Changes in bone turnover markers in HIV infected children vary as a consequence of study 
cohort characteristics but suggest a significant association between increased bone turnover 
markers and low bone mass [86, 97, 98]. Additionally, in vitro research has suggested that 
the HIV-1 virus and its proteins may alter bone turnover by directly influencing 
osteoclastogenesis [99-101], osteoclast activity [102, 103], osteoblast activity [104-107], 
and mesenchymal stem cells [105, 108-112]. 
A relatively new field known as osteoimmunology has highlighted the interactions 
between the immune system and the skeletal system. Applying this lens to the study of 
HIV and bone loss has provided considerable insight into the mechanism underlying this 
pathophysiology. Osteoclastogenesis requires permissive concentrations of macrophage 
colony-stimulating factor (M-CSF) and binding of receptor activator of NF-κB (RANK) 
ligand (RANKL) with its receptor, RANK, on osteoclast precursors. Osteoprotegerin 
(OPG) acts as a physiological decoy receptor for RANKL thereby inhibiting osteoclast 
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differentiation. The ratio of RANKL and OPG is therefore a key factor in determining the 
downstream levels of bone resorption. Recent work has shown that T cells and B cells are 
both sources of OPG and instrumental in moderating bone resorption via the RANKL/OPG 
ratio [113]. With HIV infection, it has been suggested both pre-clinically [24] and clinically 
[114, 115] that bone loss in the HIV infected population is due in part to loss of or 
dysfunctional T cells and reduction in OPG production by B cells. The mechanism of ART-
mediated bone loss is not clear but suggested to be a consequence of early immune 
reconstitution whereby a rapid recovery of T cells induces bone loss [116]. The exact role 
that chronic immune activation plays in bone loss in the setting of successful ART 
treatment remains unclear [117].  
Changes in bone remodelling dynamics influence bone microarchitecture and can 
negatively impact bone strength. In an early study looking at bone histomorphometry of 
transiliac bone biopsies from HIV infected individuals, Serrano et al. found a difference in 
trabecular spacing with greater spacing in HIV bone accompanied by histomorphometric 
measures indicating decreased bone turnover that worsened with HIV disease severity 
[118]. Recently, a method known as trabecular bone score (TBS) was introduced that takes 
two-dimensional DXA images of the lumbar spine and extracts a gray-level textural index, 
and it has been shown to correlate to 3D measures of bone microarchitecture and predict 
fracture risk [119]. Using TBS, Sharma and colleagues found that women infected with 
HIV were more likely to have lower TBS even after adjusting for age and menopausal 
status but no difference in percent change in TBS per year was found over the 5 years of 
the study when compared to uninfected women [120]. Although TBS provides more 
information than BMD, it still falls short in quantifying bone microarchitecture. Using 
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high-resolution peripheral quantitative computed tomography (HR-pQCT) can provide a 
more accurate assessment of BMD than DXA as well as microstructural level detail of 
trabeculae. Calmy et al. utilized HR-pQCT with HIV positive and negative premenopausal 
Swiss Caucasian women to analyse the bone at the distal tibia and the distal radius [121]. 
They found decreased trabecular BMD and number and increased trabecular separation at 
the distal tibia as well as significantly reduced cortical BMD at the distal radius with similar 
but non-significant reductions in trabecular measures. HIV positive women also had lower 
lumbar spine BMD but no differences in proximal femur BMD. Similarly, in a group of 
postmenopausal Hispanic and African American women, Yin and colleagues found 
reduced BMI-adjusted aBMD Z-scores at the lumbar spine, total hip, and ultradistal radius 
in the HIV group with higher levels of bone resorption markers [122]. However, in this 
cohort, they only found differences in the tibia with HIV women having decreased cortical 
bone area and thickness with a trend towards decreased cortical BMD. Given the 
differences in the demographics in the two studies, it is difficult to make useful 
comparisons. Nevertheless, the results suggest altered bone microarchitecture in HIV 
infected women that may predispose this population to fragility fractures. 
In young men aged 20-25 years on ART, Yin et al. used HR-pQCT to scan the non-
dominant distal radius and distal tibia and found significantly lower trabecular BMD, 
cortical thickness, and trabecular thickness at both sites as well as greater trabecular 
spacing at the distal tibia [87]. Using a technique for HR-pQCT called individual trabeculae 
segmentation (ITS)-based morphological analysis [123-125], they reported significantly 
reduced trabecular plate measures in HIV infected groups with no differences in trabecular 
rod measures. Using micro finite element analysis (FEA), they further found whole bone 
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(i.e., cortical and trabecular bone) stiffness to be reduced in the HIV infected groups at the 
radius and reduced trabecular bone stiffness at both sites. Importantly, this study highlights 
that early life infection with HIV – whether perinatally or behaviorally – compromises 
bone mass, microarchitecture, and mechanics at the time of peak bone mass attainment. 
Studies on older men have found that middle-aged [126] and elderly [127] men infected 
with HIV have similarly disrupted cortical and trabecular morphologies. Additionally, Co-
infection with the hepatitis C virus (HCV) was shown in both men [128] and women [129, 
130] to exacerbate the deficits to bone morphology more than HIV infection alone. 
Although bone microarchitecture is known to contribute to bone strength, little research – 
aside from micro FEA estimations – has been done to assess bone mechanical properties 
in HIV infected persons. Güerri-Fernández et al. used microindentation to assess tissue 
level bone material properties in ART-naïve HIV infected patients and controls in Spain 
and found that bone material strength index (BMSi) values were lower in HIV infected 
individuals independent of BMD [131]. 
2.3.2 Bone Healing 
Although the risk for fracture and the incidence of fracture are significantly greater 
in the HIV positive population [132], it is unclear whether fracture healing is negatively 
impacted in this group. Richardson et al. posited that there may be several pathways to 
impaired healing in HIV patients including low bone mass, effects on the immune system, 
and other comorbidity effects [133]. In the context of osteoporosis, animal studies looking 
at both postmenopausal estrogen-deficient and senile osteoporosis have shown delayed 
healing and impairment of healing outcomes including early mesenchymal stem cell 
recruitment and differentiation and callus formation and remodelling [37, 134]. Given the 
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critical inflammatory phase of fracture healing, it is not surprising that immune cells play 
an important role in fracture healing [135]. Specifically, depletion of T and B lymphocytes 
expedites bone healing [136] but at the expense of the quality of callus formation and 
mineralization [137], and they have been shown to be present in the fracture callus at all 
phases of healing except during soft callus formation and in cartilaginous regions [138]. 
Indeed, both systemic and local chronic inflammation can impair fracture healing but the 
underlying mechanisms have yet to be fully elucidated [37, 139].  
Clinically, successful fracture healing is assessed radiographically and by clinical 
observation [140]. Impaired bone healing is subsequently categorized as delayed union, 
nonunion, or malunion [141]. Several clinical investigations have included this question of 
impaired bone healing in their studies with HIV infected individuals but the findings are 
inconclusive [13]. The predominant concern for orthopaedic surgeons has been infection 
given the possible immune-compromised status of HIV positive individuals. Sufficient 
research has been put forth showing low risk of infection with closed fractures but there is 
an increased risk for infection in open fractures. With regards to impaired healing across 
multiples studies, the rates of nonunion ranged from 0% to 33%. However it is difficult to 
draw conclusions from these studies because of the many limitations inherent with them 
including small sample sizes, poor experimental design, poor or no criteria for assessing 
fracture union, and large variation in follow-up duration [13]. 
2.4 HIV and Animal Models 
The search for an animal model that can be used as a surrogate for HIV-1 infection 
in humans began soon after the term AIDS was used to describe the disease. The closest 
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animal to humans is the chimpanzee which can be infected with the simian 
immunodeficiency virus (SIVcpz), the origin of HIV-1; however, it is an endangered 
species, rarely develops disease in captivity, and requires significant time, expense, and 
expertise to conduct research [15]. Other non-human primates have been found to host SIV 
and even chimeric viruses that are a combination of SIV and HIV genomes (SHIVs) have 
been created in the effort to find a model that can mimic the human condition. However, 
SIV, while similar to HIV, is genetically different and use of these large animal models are 
again limited by cost and technical expertise as well as small sample sizes [15, 142]. Other 
animals have a naturally occurring immunodeficiency virus including sheep, goats, cows, 
horses, and cats, but they are limited in their relevance to humans and in the practicality of 
their use [15, 143]. In the search for a small animal model, humanized mouse models were 
developed [142]. Considerable understanding in HIV/AIDS biology and therapy has been 
gained from the use of these mouse models, but they are challenging to use because of the 
technical expertise needed to produce and the inability to be bred to maintain phenotype 
[14, 23]. 
HIV-1 transgenic (tg) animals bypass the considerable complications and barriers 
to research that the aforementioned models have [144]. Transgenic animals are non-
infectious, easily maintained as colonies, and have been shown to mimic elements of the 
human condition with HIV infection, specifically HIV-associated comorbidities. In the 
HIV-1 tg mouse model, cardiovascular disease [18, 19], renal dysfunction [16, 20], 
lipodystrophy [145], and B cell lymphoma [146, 147] have been studied. The HIV-1 tg rat 
model has been used extensively to study a variety of HIV-associated conditions including 
immune dysfunction [17, 148-150], cardiovascular disease [21, 151, 152], pulmonary 
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disease [153, 154], neurocognitive disorders [144, 155], liver disease [156, 157], and 
nephropathy [22, 158]. Despite the inability of rodents to be infected with HIV-1, the HIV-
1 transgenic rodent models have proven useful for studying the effects of viral products 
especially in the context of a long-term chronic condition, and they have the added benefit 
of being more easily genetically modified than other models of HIV/AIDS to study specific 
viral and host factors [6, 159]. 
However, little bone-related research has been conducted in the HIV-1 tg mouse 
and rat models. In one study using the HIV-1 tg mouse, the findings suggested 
dysfunctional bone-derived mesenchymal stromal cells [109], and in a different HIV 
transgenic mouse, the researchers observed that the ribs in HIV tg mice were “thin and 
friable” compared to normal mice [160]. Most recently, Raynaud-Messina et al. utilized 
both humanized and transgenic mouse models to show that osteoclasts can be infected by 
HIV-1 and that this can lead to Nef-mediated bone fragility, decreased bone density, and 
increased osteoclast number and activity [103]. Interestingly, in tibias from a humanized 
mouse model, Springer et al. reported lower hardness, ultimate load, and stiffness values 
for HIV positive animals compared to controls [161]. Studies using the HIV-1 tg male rat 
showed that this model recapitulates an osteoporotic bone phenotype via heightened 
osteoclast activity [24, 162]. Therefore, there is an opportunity to investigate in vivo effects 




CHAPTER 3. SKELETAL PHENOTYPE AND FRACTURE 
HEALING IN AN HIV-1 TRANSGENIC MOUSE 
3.1 Introduction 
HIV/AIDS continues to be a worldwide epidemic with over 36 million people in 
the world living with HIV [1]. Although the advent of antiretroviral therapy (ART) has 
dramatically extended the life expectancy those infected with HIV [3], this population is 
now faced with comorbidities traditionally associated with aging including osteoporosis 
and the risk for fragility fractures [4, 163]. In their work reporting the significance of 
osteoporosis in the HIV infected population, Brown and colleagues found that HIV infected 
patients were 6.4 times more likely to have reduced bone mineral density (BMD) and 3.7 
times more likely to have osteoporosis [66]. Later studies have confirmed this increased 
prevalence at varying rates [67] and consequently, there is a greater risk for fracture [164]. 
Bone quality measures including bone microarchitecture and bone mechanical properties 
are known to be critical factors in skeletal fragility especially in osteoporotic patients [28, 
165, 166]. However, considerable variability exists between clinical studies due to 
challenges with clinical studies in the HIV infected population including traditional risk 
factors for osteoporosis and the complicated interplay between HIV infection itself and 
ART on bone loss [113].  
The rates for fracture in the HIV positive population are likewise increased 
compared to the HIV negative population [9, 132]. Whether this patient population 
subsequently experiences complications with recovery after fracture is controversial. Some 
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speculation has been made regarding an association between HIV and bone healing [133], 
but the limited number of studies including fracture nonunion in their reports have found 
significantly variable results with some studies reporting no prevalence of nonunion and 
others reporting up to 33% prevalence of nonunion within their HIV positive cohorts [13]. 
Additionally, many of these studies suffer from poor experimental design, low sample 
sizes, and a lack of clear definitions for assessing fracture union and nonunion. It is 
therefore unclear whether there is an effect of HIV on fracture healing. 
Animal models thus provide an opportunity to study the effects of HIV on bone that 
would prove too difficult to isolate in the clinical setting. Current animal models of HIV 
infection (i.e., nonhuman primates and humanized mouse models) can be technically 
challenging and resource prohibitive and have been traditionally used in cure research [14, 
15]. The development of noninfectious transgenic animals for HIV research has provided 
the opportunity to study the effects of HIV without the risk or cost of studying active HIV 
infection. As previously stated, HIV-1 tg mice have been used to study multiple HIV-
associated comorbidities [16, 18-20, 145-147]. Less work has presented bone-relevant 
research with the few studies suggesting abnormal bone cell function and bone integrity 
that may result in compromised bone function [16, 103, 109, 160]. 
In this study, our objective was to characterize the skeletal phenotype of the HIV-
1 tg mouse to determine if the constitutive HIV-1 gene expression in these animals 
negatively impacts their bone structure and function. Specifically, we first examined the 
bone structural and mechanical properties in order to show that HIV-1 tg mice exhibit a 
skeletal phenotype consistent with changes in bone microarchitecture seen with clinical 
osteoporosis. We hypothesized that HIV-1 tg mice will have deleterious alterations to bone 
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microarchitecture accompanied by decreased bone mechanics. Secondly, we investigated 
the bone healing process in the HIV-1 tg mice using a closed femoral fracture model with 
intramedullary stabilization. We further hypothesized that bone healing would be impaired 
in HIV-1 tg mice. 
3.2 Materials and Methods 
3.2.1 HIV-1 Transgenic Mouse Model 
For the bone structure and mechanics investigation, male hemizygous NL4-3Δ 
gag/pol HIV-1 transgenic (tg) (n=10, HIV) and wild-type littermate (n=10, WT) mice in 
the FVB/N background were obtained from Dr. Roy Sutliff (Atlanta Veterans Affairs 
Medical Center, Decatur, GA) and Dr. Rudy Gleason (Georgia Institute of Technology, 
Atlanta, GA). All mice were euthanized at approximately 10-12 weeks of age. Hemizygous 
mice appear normal at birth but present with progressive renal dysfunction and 
glomerulopathy similar to that of HIV-associated nephropathy seen in humans [16, 20]. 
Compared to wild-type mice, homozygous HIV-1 Tg mice are born smaller, have 
decreased food intake, and typically die within 40 days after birth [16]. Only hemizygous 
mice were used in this study. 
For the long bone fracture healing investigation, male HIV-1 tg (HIV) and wild-
type littermate (WT) mice in the C57BL/6 background were used. Briefly, HIV-1 Tg mice 
that were backcrossed eight generations from the FVB/N background to a C57BL/6 
background were obtained from Dr. Roy Sutliff (Veterans Affairs Medical Center, Atlanta, 
GA) [167]. A total of 24 animals per group approximately 12 to 14 weeks of age were used 
in this study. Animals were housed in a quarantined room on a 12:12 hour light/dark 
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schedule and provided food ad libitum. Procedure for closed fracture was previously 
reported and adapted for this study [168]. Briefly, mice were anesthetized via isoflurane 
inhalation, and the right hind limb was cleaned of hair by shaving and using depilatory 
cream (Nair). The surgical site was cleaned before an incision was made to then expose the 
femur via gross dissection. An intramedullary pin using K-Wire (Key Surgical) 
approximately 0.7 mm in diameter was inserted into the intramedullary canal through the 
distal end of the femur. Using a gigli wire saw (RISystem) approximately 0.22 mm thick, 
a mid-diaphyseal osteotomy was created, contact between bone ends was ensured, and 
stability of the pin was checked. The contralateral leg was left intact. Mice were allowed 
to recover on a heating pad, and after ambulation was confirmed, returned in their cages to 
the housing room. Any animals with evidence of intramedullary pin instability or 
displacement were removed from the study. 
Two different mouse strains were utilized in this study due to restrictions on 
availability of samples and animal health and welfare concerns. HIV-1 tg mice on the 
FVB/N background presented with a more severe disease-like state resulting in death by 4 
months. In contrast, HIV mice on the C57BL/6 background do not present with early 
cataracts like the FVB/N background HIV-1 tg mice and need to be genotyped by tail snip. 
All procedures were approved by the Georgia Institute of Technology and the Atlanta 





3.2.2 X-Ray Radiographs and MicroCT 
For the bone structure and mechanics investigation, the left femur and lumbar 
spines were harvested from each animal, wrapped in saline soaked gauze and stored at -
20ºC until needed. Femurs and vertebrae were cleaned of soft tissue and scanned using 
micro-computed tomography (microCT, µCT 40 system, Scanco Medical) at a medium 
resolution with a voxel size of 12 µm, a voltage of 55 kVp, and a current of 145 μA. Using 
built-in software, a 1 mm section of the femur mid-diaphysis was evaluated for cortical 
bone morphology (bone area, BA; bone marrow area, MA; total area, TA; cortical 
thickness, Ct.Th; moment of inertia, MOI; polar moment of inertia, pMOI; and mineral 
density). The distal femur was evaluated at the metaphysis and epiphysis using a 0.6 mm 
section measured from the growth plate for trabecular microarchitecture (trabecular 
number, Tb.N; trabecular thickness, Tb.Th; trabecular spacing, Tb.Sp; structure model 
index, SMI; bone volume fraction, BV/TV; connectivity density, Conn.D; and mineral 
density). L6 vertebrae were isolated from the lumbar spine and cleaned of soft tissue. The 
central 2.4 mm section of the L6 vertebrae was also measured for trabecular measures. 
Cortical bone was excluded from trabecular analysis using an automated segmentation 
algorithm [169]. Contours were visually inspected for accuracy and manually adjusted as 
necessary. 
For the fracture healing study, animals were x-rayed in vivo (Bruker Xtreme 
Imaging System) every week after fracture surgery to qualitatively assess fracture stability 
and progression of healing. Mice were euthanized at Week 2 (n = 10 WT, n = 10 HIV) and 
Week 4 (n = 10 WT, n = 8 HIV) using CO2 inhalation following standard protocols. Both 
hind limbs were harvested, wrapped in saline soaked gauze, and stored at -20ºC until 
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needed. Prior to scanning, hindlimbs were allowed to thaw in PBS at room temperature. 
Femurs were isolated and cleaned of soft tissue before the intramedullary pin was carefully 
removed. Fracture calluses were scanned in a humid chamber at a resolution of 20 µm, a 
voltage of 55 kVp, and a current of 145 μA (μCT 40 system, Scanco Medical). Four WT and 
three HIV samples were excluded from microCT analysis due to errors in scanning that 
were not able to be resolved because biomechanical testing was performed immediately 
after the scans. The entire fracture callus was included by manually contouring the outer 
boundary, and the native cortical bone was contoured for exclusion from analysis. 
Following a procedure previously used [168, 170], new mineral formation was defined as 
50% of the native cortical bone density. Using this threshold and built-in software, the 
fracture callus was segmented and analyzed for total callus volume, mineralized callus 
volume, mineral density, and polar moment of inertia.  
3.2.3 Mechanical Testing 
Femurs and L6 vertebrae intended for skeletal phenotype evaluation were 
mechanically tested to failure under displacement control. Femurs were allowed to thaw to 
room temperature prior to 3-point bending at a rate of 1 mm/min with a span of 6.2 mm 
between lower supports (ELF 3200, Bose EnduraTEC). Femurs were tested posterior side 
down and were loaded at the mid-diaphysis. Vertebrae were allowed to thaw to room 
temperature, then transverse and posterior processes were removed. Cranial and caudal 
growth plates were removed using a cutting slab to ensure parallel surfaces and a constant 
height of 2 mm. The L6 vertebrae were glued to the bottom compression plate before 
testing to failure using compression testing at a rate of 1 mm/min. During mechanical 
testing, all samples were kept moist with PBS. Structural properties (ultimate load, 
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stiffness, yield load, post-yield displacement, energy to ultimate load, and energy to failure 
load) were calculated directly from the load-displacement curve where appropriate. 
Derived material properties (Ultimate stress, elastic modulus, and toughness to ultimate 
stress) were calculated from the load-displacement data using standard equations [171]. 
Fracture callus samples and intact contralateral control femurs were mechanically 
tested to failure under torsion following previously reported methods [168]. Briefly, 
samples were cleaned of any remaining soft tissue from bone ends and potted in Wood’s 
metal (Alfa Aesar) in custom fixtures with a gauge length of 6.5 mm. Samples were tested at 
a rate of 3 degrees per second until failure or until 60 degrees of rotation using an ELF 
3220 testing system (Bose EnduraTEC). Samples were kept moist using PBS during 
mechanical testing. Mechanical properties were calculated from the torque-rotation data 
(maximum torque, torsional stiffness, rotation at maximum torque, and energy to 
maximum torque).  
3.2.4 Vascular Perfusion and Analysis 
Following previously reported methods [168], we analysed fracture callus 
vascularization in animals from the fracture healing study (n = 4 WT, n = 4 HIV). Mice 
were euthanized via CO2 inhalation at Week 1 post fracture and immediately perfused 
sequentially with physiological saline, 10% neutral buffered formalin, and again with 
saline. A yellow-colored, radiopaque, lead chromate compound (Flow Tech Inc.) was then 
injected with steady pressure into the vasculature until yellowing was apparent on the 
internal organs and pads of the feet. Animals were stored at 4°C overnight to allow for 
polymerization of the contrast agent. Fractured femurs were isolated and intramedullary 
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pins carefully removed before storing in 10% neutral buffered formalin for 48 hours at 4°C. 
Samples were then soaked in a formic acid solution with citrate buffer (Newcomer Supply) 
under gentle agitation until decalcification was confirmed via soft x-ray imaging. Samples 
were then scanned at a voxel size of 10.5 µm and the callus was isolated via manual 
contours of 2-D images. 3-D reconstructions were evaluated for vessel volume, vessel 
volume fraction, vessel diameter, and vessel connectivity. 
3.2.5 Statistics 
All data are presented as mean ± SEM. Statistical analyses were performed using 
SPSS Statistics 24. Bone microarchitecture, bone mechanics, and microCT vascularization 
data were analysed using unpaired two-sample Student’s t-tests or Mann-Whitney U tests. 
Fracture callus microCT data and biomechanics were analysed using two-way ANOVA as 
performed by the univariate general linear model in SPSS. Pairwise comparisons were 
adjusted using the Bonferroni correction. A significance level of 0.05 was set for all 
analyses. 
3.3 Results 
3.3.1 Bone Microarchitecture 
In order to evaluate bone structural differences in cortical and trabecular bone, we 
scanned the femoral mid-diaphysis, distal femur, and L6 vertebra of each animal. The 
femoral mid-diaphysis was evaluated for cortical bone architecture measures. Compared 
to WT animals, HIV animals had severely compromised cortical bone structure with 
thinner cortices (-38.2%, p < 0.001, Ct.Th) and less bone measured by average cross-
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sectional cortical bone area (-27.9%, p < 0.01, BA) (Figure 3-1). Interestingly, the total 
cross-sectional area (p = 0.638, TA) did not differ between WT and HIV animals 
suggesting that while HIV mice may weigh less and have slightly shorter femurs (Table 
B-1), the transverse growth of the bone is similar. Accordingly, the larger cross-sectional 
marrow area (12.6%, p < 0.01, MA) in HIV mice may be a consequence of greater 






Figure 3-1: (A) Representative microCT 3D reconstructions of femur mid-diaphysis. (B) 
MicroCT evaluation of femur mid-diaphysis. n = 10 per group. Error bars indicate SEM. * 
indicates significant difference between groups (p < 0.05). Ct.Th = cortical thickness; MOI 
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We scanned the distal femur to examine two different regions of trabecular bone: 
the epiphyseal area and the metaphyseal area. At both sites of trabecular bone, HIV mice 
had less bone as measured by bone volume fraction (epiphysis: -33.0%, p = 0.011; 
metaphysis: -41.1%, p = 0.014; BV/TV) and thinner trabeculae (epiphysis: -19.2%, p < 
0.01; metaphysis: -13.3%, p =0.035; Tb.Th) when compared to WT mice (Figure 3-2 and 
Figure 3-3). No other differences were found at the epiphysis but significant alterations to 
trabecular architecture were found at the metaphysis including greater average structure 
model index (SMI) values (p = 0.018) and decreased connectivity density (-49.5%, p = 
0.049, Conn.D) in HIV femurs (Figure 3-3). SMI values are an estimation of the average 
plate-like (SMI = 0) or rod-like (SMI = 3) characteristic of the trabecular bone analyzed. 
For example, trabecular bone in the epiphyseal compartment is more plate-like in nature 
(Figure 3-2) while in the metaphyseal region, the trabeculae are more rod-like (Figure 3-3). 
These site-specific differences within the same bone may be reflective of the different 
mechanical and biological environment each region experiences. Additional data are 






Figure 3-2: (A) Representative microCT 3D reconstructions of distal femur epiphysis. (B) 
MicroCT evaluation of trabecular bone at distal femur epiphysis. n = 10 per group. Error 
bars indicate SEM. * indicates significant difference between groups (p < 0.05). BV/TV = 
bone volume / total volume, i.e. bone volume fraction; Tb.N = trabecular number; Tb.Th 
= trabecular thickness; Tb.Sp = trabecular spacing; Conn.D = connectivity density; SMI = 







































































































































































































































































































1 0 0 0
1 1 0 0
1 2 0 0






















W T H IV
B A 



































































Figure 3-3: (A) Representative microCT 3D reconstructions of distal femur metaphysis. 
(B) MicroCT evaluation of trabecular bone at distal femur metaphysis. n = 10 per group. 
Error bars indicate SEM. * indicates significant difference between groups (p < 0.05). 
BV/TV = bone volume / total volume, i.e. bone volume fraction; Tb.N = trabecular number; 
Tb.Th = trabecular thickness; Tb.Sp = trabecular spacing; Conn.D = connectivity density; 
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 We further investigated effects on trabecular bone by scanning the trabecular 
compartment of L6 vertebra in the lumbar spine (Figure 3-4). Similar to the results found 
in the distal femur metaphysis, the BV/TV in HIV mice was lower (-24.8%, p < 0.01), 
trabeculae were significantly thinner (-27.1%, p < 0.001, Tb.Th), and SMI values were 
greater (p < 0.001) when compared to WT mice (Figure 3-4). In contrast to the metaphysis, 
we found HIV vertebrae had lower mineral density values (-6.9%, p < 0.001) and greater 
trabecular connectivity (40.3%, p < 0.01, Conn.D) which may be a consequence of greater 
resorption of plate-like trabeculae leading to an increased number of more rod-like 
trabeculae and less mature mineralized tissue. Although not statistically significant, 
comparison of the HIV vertebrae average trabecular number (15.7%, p = 0.245, Tb.N) and 
trabecular spacing (-10.9%, p = 0.156, Tb.Sp) values with WT vertebrae appears to support 





    
  
Figure 3-4: (A) Representative microCT 3D reconstructions of L6 vertebra. (B) MicroCT 
evaluation of trabecular bone at L6 vertebra. n = 10 WT; n = 9 HIV. Error bars indicate 
SEM. * indicates significant difference between groups (p < 0.05). BV/TV = bone volume 
/ total volume, i.e. bone volume fraction; Tb.N = trabecular number; Tb.Th = trabecular 
thickness; Tb.Sp = trabecular spacing; Conn.D = connectivity density; SMI = structure 
model index. 
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3.3.2 Bone Biomechanical Phenotype 
Through whole bone biomechanical testing, we sought to determine if bone 
mechanical properties were altered in HIV mice. Femurs were tested in three-point bending 
to assess cortical bone strength. Compared to WT mice, HIV mouse femurs were 
structurally weaker with lower ultimate load values (-19.8%, p = 0.023) and a 14.9% 
average lower stiffness value (p = 0.165) (Figure 3-5). Additionally, femurs from HIV 
animals absorbed less energy prior to failure (-28.8%, p = 0.014).  However, we were 
unable to detect differences in derived material properties, suggesting that the diminished 
cortical bone mechanical properties in HIV femurs are due to the changes found in cortical 







Figure 3-5. Biomechanical properties of whole femurs tested in three-point bending. (A) 
Measured structural properties. (B) Estimated derived material properties.  n = 9 WT; n = 
10 HIV. Error bars indicate SEM. * indicates significant difference between groups (p < 
0.05). 
 In order to assess composite cortical and trabecular bone strength, we tested isolated 
whole vertebrae in displacement controlled compression. We found significantly weaker 















































































































































































































































































































































































































































































































































































(-51.8%, p = 0.012) values (Figure 3-6). While not statistically significant, HIV vertebrae 
also had an average 29.9% reduction in stiffness (p = 0.089) and 43.7% decreased energy 
to ultimate load (p = 0.189). Similar to the femur, no significant differences were found 
when comparing derived material properties, again suggesting bone mass and 
microarchitectural changes are driving changes in mechanics. Additional data are presented 




   
   
 
Figure 3-6. Biomechanical properties of L6 vertebrae tested in compression. (A) Measured 
structural properties. (B) Estimated derived material properties.  n = 7 WT; n = 8 HIV. 














































































































































































































































































































































































































3.3.3 Radiographic and MicroCT Evaluation of Fracture Healing 
Digital 2-D radiographs were used to qualitatively assess pin stability and in vivo 
bone healing. No visual differences in the healing process were observed between WT and 
HIV animals (Figure 3-7). In contrast, analysis of microCT scans revealed significant 
differences in fracture healing between groups. At two weeks post fracture, although on 
average decreased in HIV animals, no differences were found in callus volume (WT: 44.91 
± 5.32 mm3; HIV: 34.95 ± 4.39 mm3; p = 0.082) or in mineralized callus volume (WT: 
2.94 ± 0.33 mm3; HIV: 2.16 ± 0.25 mm3; p = 0.355) (Figure 3-8). At four weeks post 
fracture, callus volume for both groups was expectedly diminished from two weeks, but 
mineralized callus volume was found to be significantly lower in HIV mice (WT: 4.97 ± 
0.68 mm3; HIV: 3.6 ± 0.42 mm3; p = 0.041). This difference was maintained even when 
comparing the percentage of mineralized tissue present in the callus between groups (WT: 
22.84 ± 3.87 %; HIV: 14.93 ± 1.91 %; p = 0.039). The cross-sectional distribution of 
mineralized tissue within the callus as measured by polar moment of inertia (pMOI) was 
also significantly different between WT and HIV animals at Week 4 (WT: 1.07 ± 0.18 
mm4; HIV: 0.6 ± 0.08 mm4; p < 0.01). No differences in average mineral density were 
found at any time point. 
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Figure 3-7. Representative 2-D radiographs of fracture healing 
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Figure 3-8. MicroCT evaluation of fracture healing. Week 2: n = 6 WT, n = 7 HIV; Week 
4: n = 10 WT, n = 8 HIV. Error bars indicate SEM. Scale = 1 mm. * indicates significant 
difference between groups (p < 0.05). 
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3.3.4 Fracture Callus Biomechanical Properties 
We performed torsional mechanical tests on fractured femurs to assess restoration 
of functional mechanics. Comparison of fractured femurs revealed an overall effect of HIV 
status for maximum torque (p = 0.025), energy to maximum torque (p = 0.029), and polar 
moment of inertia (p < 0.01, pMOI). Torsional stiffness data likewise warranted further 
analysis (p = 0.051), but the rotation to maximum torque did not (p = 0.380). As expected, 
no differences were found at Week 2 after fracture surgery (Figure 3-9). However, HIV 
fractured femurs were found to be mechanically weaker by Week 4 with lower maximum 
torque, torsional stiffness, and work to maximum torque. Neither HIV nor WT fractures at 
4 weeks healed to the level of intact femur rotational mechanical properties (Table B-1). 
  
    
Figure 3-9. Biomechanical properties of fractured femurs. Week 2: n = 10 WT, n = 10 HIV; 
Week 4: n = 10 WT, n = 8 HIV. Error bars indicate SEM. * indicates significant difference 
between groups (p < 0.05).  
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3.3.5 Early Vascularization of Fracture Callus Analysis 
Our microCT findings suggested that HIV animals may have deficiencies in early 
fracture callus formation and overall decreased mineralization resulting in compromised 
mechanical properties at four weeks post fracture. Taking these results together, we asked 
whether early vascularization in the fracture healing process could explain these later 
effects. Thus, utilizing contrast-agent enhanced microCT angiography, we quantitatively 
evaluated the vascular volume and morphology within the entire fracture callus at one week 
post fracture. No differences were found between groups for any measures (Figure 3-10). 







Figure 3-10. MicroCT analysis of Week 1 fracture callus vascularization. (A) 
Representative 3-D microCT reconstruction. (B) Quantitative evaluation of callus 
vasculature. n = 4 WT; n = 4 HIV. Error bars indicate SEM. 
 
 




















































W T H IV


































































V e s s e l V o lu m e  F ra c tio n  - W T
V e s s e l V o lu m e  F ra c tio n  - H IV
W T H IV


























































V e s s e l T h ic k n e s s  -  W T
V e s s e l T h ic k n e s s  - H IV
W T H IV











































C o n n .D  -  W T
C o n n .D  -  H IV





Skeletal health in the HIV infected population is challenged by an increased risk 
for osteoporosis and fracture. Whether fractures in this group are at greater risk for 
impaired healing is unknown. We investigated whether an HIV-1 tg mouse with a gag-pol 
deleted HIV-1 provirus would present with similar decrements to bone microarchitecture 
and biomechanics as seen in humans, and we further sought to determine if bone healing 
is altered in this mouse model of HIV. We showed that HIV-1 tg mice had lower bone mass 
as reflected in measures of cortical bone area and trabecular bone volume fraction. HIV 
animals were also found to have thinner cortical bone and lower moment of inertia leading 
to reduced long bone structural mechanical properties. Additionally, trabecular bone in the 
distal femur was found to be altered with significant differences in the metaphysis. The 
trabecular compartment of the L6 vertebra likewise had thinner trabeculae with greater 
SMI values. Biomechanical testing of the vertebra revealed significant reductions in 
structural mechanical properties. We further showed a significant impairment of bone 
healing in the HIV animals that resulted in lower fracture callus mechanics by 4 weeks post 
injury.  
Bone microarchitecture contributes to bone quality and is a key determinant of 
fracture risk [28, 64]. In the HIV-1 tg mouse, we found a reduction in cortical thickness 
and cortical area with a corresponding increase in marrow area. Interestingly, the average 
total cross-sectional area did not differ between groups. This may suggest similar periosteal 
growth characteristics between WT and HIV mice but a significantly greater level of 
endosteal resorption in the HIV mice. To study alterations in trabecular bone, we focused 
on the distal femur epiphysis and metaphysis and the L6 vertebra. At all sites, we found 
 50 
decreased bone volume fraction and trabecular thickness in HIV mice and no differences 
in trabecular number or spacing. Differences in connectivity density and SMI were 
reflective of the unique physiologic environment seen by each skeletal site. HIV mice 
tended to have higher SMI values suggestive of a more rod-like characteristic although the 
epiphysis and L6 vertebra had a clear plate-like average morphology and the metaphysis 
had a clear rod-like average morphology. This is suggestive of a greater level of remodeling 
in the metaphysis with less direct mechanical loading. Changes in connectivity density that 
accompany decreased BV/TV may be a consequence of perforations of trabeculae which 
leads to an increase in connectivity or loss of trabecular struts leading to a decrease in 
connectivity. HIV animals had less connections in the metaphysis possibly reflecting the 
latter situation and more connections in the L6 vertebra reflecting the former scenario. 
There was no difference in connectivity density in the epiphysis suggesting that the 
reduction in BV/TV was mediated mainly by trabecular thinning in HIV mice. Together, 
these findings show an overall decrease in bone mass primarily as a consequence of 
thinning of both cortical and trabecular bone with site-specific negative changes to 
trabecular microarchitecture.  
Unlike humans, mice continue to experience longitudinal bone growth after sexual 
maturity at 6-8 weeks and reach peak bone mass between 4 and 6 months of age [172]. The 
mice used to investigate bone structure and mechanics were 10-12 weeks of age, falling 
just short of the reported peak bone mass seen in other mice. However, local attainment of 
peak bone mass depends on the anatomical site and the differing ratios of cortical to 
trabecular bone [173]. Trabecular bone compartments tend to reach peak bone mass earlier 
in life and slowly decrease with age while adapting to loads by adjusting geometry and 
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orientation [173]. Thus, our findings suggest either an early deficit in bone mass accrual or 
accelerated loss of bone with age in HIV-1 tg mice. Longitudinal studies to investigate 
changes in bone microarchitecture with age are needed to determine how and when the 
deficits in bone microarchitecture occur and if there is an interplay between age and 
expression of HIV-1 proteins in the HIV-1 tg mouse. 
It is possible that bone remodeling is altered as a consequence of HIV-1 gene 
expression in the HIV-1 tg mouse used in this study. This model expresses HIV-1 genes in 
skin, muscle, tail, and less abundantly in kidneys, intestine, and thymus [174]. Cheng et al. 
showed that mesenchymal stromal cells isolated from compact bone from HIV-1 tg mice 
expressed HIV-1 genes and subsequently had impaired proliferation and differentiation 
[109]. In a different transgenic mouse expressing HIV-1 Nef, osteoclast resorption was 
enhanced resulting in reduced bone density and increased bone fragility [103]. Multiple 
studies have shown in vitro HIV-1 protein effects on osteoclastogenesis [99-101], 
osteoclast activity [102], osteoblast activity [104-107], and mesenchymal stem cells [105, 
108, 110-112] that suggest imbalanced bone turnover processes through increased bone 
resorption and impaired bone formation. Bone remodeling can also be influenced by 
immune cells through the immuno-skeletal interface [113]. Specifically, T and B cells are 
involved in modulation of osteoclastogenesis and bone resorption by secretion of OPG and 
RANKL to influence the RANKL/OPG ratio in the local bone environment. In both HIV-
1 transgenic mice expressing either nef or tat, alterations to T cell development occur along 
with dysfunctional T cell activity and loss of peripheral CD4+ T cells [175-177]. 
Alterations to B cell development may also occur in HIV-1 tg mice used in this study, 
however the severity of this effect may be highly variable from animal to animal [146]. 
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Additionally, a pair of studies in the HIV-1 tg rat and in HIV infected humans have 
uncovered a severe imbalance in the B cell RANKL/OPG ratio that correlates with low 
BMD in humans [24, 114]. HIV-1 proteins can therefore influence normal bone remodeling 
in the HIV-1 tg mice through various avenues resulting in the bone microarchitectural 
deficits seen in our study. 
Although it is known that bone microarchitecture is critical in determining bone 
strength and ultimately fracture risk, few studies have investigated bone mechanical 
properties in HIV patients. In this study, changes in bone microarchitecture led to deficits 
in bone biomechanics in both the femur and the L6 vertebra of HIV mice. Derived material 
properties were not different between groups suggesting that structural differences in bone 
microarchitecture and not tissue level alterations contribute to the loss of mechanical 
strength in HIV bone. Our findings are supported by the few studies found in the literature. 
One study used micro finite element analysis using HR-pQCT scans of human distal radius 
and distal tibia and showed a reduction in stiffness in HIV positive young men [87]. In a 
humanized mouse model infected with HIV and treated with tenofovir disoproxil fumarate 
(TDF), femurs were tested using microindentation using the Vickers hardness test and 
tibiae were tested under three-point bending [161]. The HIV and TDF mice had the lowest 
average hardness value followed by HIV mice, but HIV mice had the lowest ultimate load 
and stiffness values. Contrary to our findings, Guerri-Fernandez and colleagues used 
microindentation at the midpoint of the midshaft anterior tibial plateau and found decreased 
bone material properties in HIV patients, especially women, that was independent of BMD 
and ART [131]. Whether bone from HIV individuals or HIV-1 tg mice have diminished 
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bone material properties leading to vulnerability to formation of microdamage and thus 
fractures warrants further study. 
Clinical studies have shown an increased risk and incidence of fractures in the HIV-
infected population [9, 132]. Spontaneous fractures do not occur in mice, but methods have 
been developed to create controlled fractures in order to investigate bone healing under 
varying conditions [26, 178]. We utilized a small long bone osteotomy with intramedullary 
pin model to create a closed fracture in HIV-1 tg mice in order to investigate bone healing. 
Early callus size and amount of mineralization at 2 weeks post fracture, although not 
significant, were 22.2% and 26.4% greater, respectively, in the WT mice, but the percent 
mineralized callus volume was not different. This suggests a similar early fracture healing 
process between WT and HIV that is attenuated in the HIV mouse. However, 4 weeks after 
bone injury showed distinctly greater mineralized callus volume in the WT mice that 
conferred sufficient structural integrity for differences in mechanical properties to be 
apparent.  
Early soft callus formation is initiated by the inflammatory phase which recruits 
osteochondroprogenitors necessary for deposition of cartilage and subsequent woven bone 
[37, 135]. It may be in the HIV-1 tg mice potentially having dysfunctional T and B cells 
that early bone healing is attenuated as reflected in the microCT data. Interestingly, 
although complete depletion of T and B cells results in faster bone healing and recovery of 
callus mechanical properties, this is because of a quicker progression of callus formation 
and mineralization that ultimately compromises the quality of the subsequent bone [136, 
137]. We did not see this accelerated healing in the HIV-1 tg mice because the adaptive 
immune system is not depleted in this model, but that does not preclude any negative 
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impact on bone healing due to dysfunctional T cells [179] or direct HIV-1 protein effects 
in this model. Studies of systemic and local chronic inflammation in mice have shown 
decreased bone healing [180] and delayed bone healing [181], respectively, suggesting an 
effect of systemic inflammation and not local chronic inflammation on bone healing in the 
HIV-1 tg mouse. Based on the findings presented here, it appeared bone healing may have 
been impaired at an earlier stage possibly due to impaired vascularization of the fracture 
region. A brief investigation of early vascularization did not show differences between 
groups, but this may be due in part to the small sample size. However, there may be an 
effect of HIV on vascularization in fracture healing and on angiogenesis in general [182-
185] that has yet to be fully investigated. 
This study has several limitations. The HIV-1 tg mouse is not a model of direct 
HIV infection and therefore does not model the human situation. However, multiple studies 
have investigated HIV associated conditions using this animal model, validating it as a 
useful model of HIV-1 infection under effective ART. Although HIV-1 gene expression 
varies by degree and anatomical location in the HIV-1 tg mouse, the localization of proteins 
in lymphoid tissues reflects that seen in HIV-infected persons [62]. The use of two different 
mouse strains was necessary due to availability of samples and animal health and welfare 
concerns. HIV-1 tg mice on the FVB/N background presented with a more severe disease-
like state resulting in death by 4 months. In contrast, HIV mice on the C57BL/6 background 
do not present with early cataracts and need to be genotyped by tail snip. However, 
C57BL/6 mice have low bone mass compared to other strains [186] and compared to 
FVB/N may have reduced bone microarchitecture measures [187] and decreased bone 
healing [188]. It would be valuable to compare the severity of disease symptoms between 
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the two strains and determine if differences in skeletal phenotype and bone healing exist, 
potentially providing insight into the genetic differences in the effects of HIV on bone 
development and healing. 
The relationship between HIV and skeletal health is complex and requires further 
study to fully elucidate. The HIV-1 tg mouse provides an attractive vehicle for this 
exploration. This small animal model is noninfectious, easily bred and maintained, and 
recapitulates conditions seen in the human condition. Our work further shows that this 
model additionally recapitulates an osteoporotic bone phenotype with altered 
microarchitecture and decreased mechanics. Notably, the HIV-1 tg mouse also presents 




CHAPTER 4. SKELETAL PHENOTYPE OF GROWING HIV-1 
TRANSGENIC RAT 
4.1 Introduction 
With effective antiretroviral therapy (ART), the HIV infected population has a life 
expectancy near that of the uninfected population [2, 3]. However, an increase in life span 
has brought with it comorbidities not seen before the era of ART including cardiovascular 
disease, renal disease, neurocognitive impairment and osteoporosis [4, 117, 163]. As the 
rate of new infections remains significant and adherence to treatment improves [189], this 
population continues to grow and age bringing with it risks to skeletal health, specifically 
osteoporosis and fracture risk, associated not just with HIV and ART but also with aging 
[117, 190]. In a trend analysis between 2003 and 2013 of US patients receiving healthcare 
coverage commercially, from Medicaid, or from Medicare, prevalence of osteoporosis and 
fractures was 7.8%, 13.3%, and 24.4% with a significant increase over time in the Medicare 
and Medicaid groups but not the commercial group [4]. Gallant et al. also found a 
significantly greater prevalence of osteoporosis and fractures in the commercial and 
Medicaid payers but not the Medicare payers when compared to uninfected controls. Given 
the proportion of patients 50 years or older in the commercial (24.7%), Medicaid (21.5%), 
and Medicare (97.4%) groups, it is apparent that the HIV population is at risk of 
osteoporosis and fractures at all ages with greater risks at older age. With an estimated 4.2 
million HIV infected individuals over the age of 50, a number that will continue to increase 
[54], there is substantial concern for an increased burden on healthcare systems [51, 191]. 
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In addition, there are over 2 million children under 15 years of age living with HIV 
globally [1]. Whether infected perinatally or early in life, this population sees the greatest 
negative impact over their lifetime on their bone health from HIV infection and ART [192]. 
Bone mass accrual occurs rapidly from birth to about the mid-20s at which point peak bone 
mass is achieved [88, 89]. Peak bone mass in turn is a critical predictor of osteoporosis and 
fracture risk [193, 194]. In a study of HIV infected males in their early 20s, Yin et al. 
showed that early infection results in a subnormal peak bone mass [87]. Several studies 
have also shown that HIV infected children and adolescents have lower bone mass 
compared to their uninfected counterparts [84-86]. Additionally, given the sex differences 
in skeletal growth [89, 195], HIV infected females may be at a greater risk of detrimental 
impacts on later life skeletal health [86, 196]. 
The laboratory rat has been used extensively to study osteoporosis [197]. Although 
rats do not naturally experience age-related bone loss, models have been developed that 
approximate closely the human condition. Reid et al published the first work establishing 
an HIV-1 rat model that was transgenic for an HIV provirus lacking the gag-pol region 
[17]. This provirus was adapted from the one used to establish the HIV-1 tg mouse utilized 
in Chapter 3 of this work [16, 20]. In contrast with the mouse, the HIV-1 tg rat exhibits 
more efficient viral gene expression especially in the lymph nodes, spleen, thymus, and 
blood [17, 144]. This model has since been used in studies on many HIV-associated 
comorbidities including cardiovascular disease [21, 151, 152], pulmonary disease [153, 
154], neurocognitive disorders [144, 155], liver disease [156, 157], and nephropathy [22, 
158]. Additionally, Peng et al. showed that the HIV-1 tg rat model could be used as a model 
for patients on effective ART [198]. Interestingly, they found that the distribution of HIV 
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gene expression varied with age changing from high expression of proteins in the spleen at 
2-3 months of age to high expression in the spinal cord and cerebellum at 10-11 months. 
Recently, Vikulina and colleagues showed that the HIV-1 tg male rat recapitulates the 
osteoporotic phenotype seen in humans [24]. They found decreased BMD and altered 
microarchitecture in male rats at 8-9 months of age but no skeletal growth or mechanics 
data were reported. 
The main objective of this study was to investigate the longitudinal skeletal changes 
of the growing HIV-1 tg female rat in order to determine if there are age-dependent changes 
in bone structure. Since the rat develops AIDS-like symptoms between the ages of five and 
nine months [17], we hypothesized that the HIV-1 tg rat would exhibit significant changes 
to bone microarchitecture between five and nine months of age that would lead to long 
term changes in bone structure and biomechanics. 
4.2 Materials and Methods 
4.2.1 HIV-1 Transgenic Rat Model 
Female HIV-1 transgenic (tg) rats (n = 10, HIV) and control F344/NHsd rats (n = 
11, WT) were purchased from Harlan Laboratories at approximately 9 to 10 weeks of age. 
Animals were used for this study beginning at four months of age and ending at twelve 
months of age. Rats were pair-housed in sterile caging under a 12 hour light/dark cycle and 
provided food (Teklad Global Diet 2918) and water ad libitum. All procedures were 
approved by the Georgia Institute of Technology Institutional Animal Care and Use 
Committee (IACUC). 
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4.2.2 Microcomputed Tomography 
Each month from 4 to 12 months of age, animals were anesthetized using isoflurane 
inhalation and scanned in vivo using microCT (vivaCT40, Scanco Medical) at a resolution 
of 21 µm, energy of 55 kVp, and current of 145 μA. A total of three skeletal sites were 
scanned each month in the left femur (mid-diaphysis, distal femur) and the L6 vertebra. 
The approximately central 1 mm region of the femoral mid-diaphysis was analyzed for 
cortical bone morphometric parameters (bone area, BA; bone marrow area, MA; total area, 
TA; cortical thickness, Ct.Th; moment of inertia, MOI; polar moment of inertia, pMOI; 
and mineral density). The distal femur at two regions of approximately 1 mm – epiphysis 
and metaphysis – and a 2.1 mm region in the L6 vertebra were analyzed for trabecular bone 
parameters (trabecular number, Tb.N; trabecular thickness, Tb.Th; trabecular spacing, 
Tb.Sp; structure model index, SMI; bone volume fraction, BV/TV; connectivity density, 
Conn.D; and mineral density). Regions of interest were identified relative to the distal 
growth plate for the distal femur and the cranial growth plate for the L6 vertebra. 
At twelve months of age, animals were euthanized via CO2 inhalation and femurs 
and lumbar spine were harvested. Samples were wrapped in saline soaked gauze and stored 
at -20°C. Samples were placed in PBS to thaw to room temperature prior to preparation for 
microCT scanning. Femurs were cleaned of all soft tissue and scanned at a 16 µm 
resolution (55 kVp, 145 μA, µCT40 system, Scanco Medical). Approximately a 1 mm 
region at the mid-femur was analyzed for cortical bone morphometric parameters. 
Vertebral bodies of L6 vertebrae were isolated and scanned at a voxel size of 12 µm. A 2.1 
mm region below the cranial growth plate was analyzed for total bone volume fraction. 
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4.2.3 Blood Collection and Serological Analysis 
Blood was collected at 4, 5, 7, 9, and 11 months of age. Observations of rats after 
the first two consecutive months of microCT scanning and blood collection suggested slow 
recovery of animal weight and vitality. In addition, one WT rat was found dead in its cage 
the following day after blood collection. Therefore, blood collection frequency was 
reduced to once every two months. No more than 10% of the total circulating blood volume 
up to 1 mL of blood was collected from the tail ventral artery of each animal [199]. Briefly, 
animals were anesthetized on a heating pad and acepromazine maleate – a vasodilator and 
mild sedative – was administered at a concentration of 1.5 mg/kg. After waiting 7 minutes, 
blood was collected into a blood collection tube and allowed to sit undisturbed for at least 
1 hour to allow for clotting. Blood samples were centrifuged at 15,000g RCF for 5 min, 
divided into aliquots, and stored at -20°C. Any serum samples that were not clear and had 
any signs of pink coloration were excluded from analysis. To assess global bone turnover 
differences, serum levels of osteocalcin and C-terminal telopeptides of type I collagen 
(CTx) were measured using commercially available ELISA kits (Rat-MID and RatLaps, 
respectively; Immunodiagnostic Systems). 
4.2.4 Mechanical Testing 
Femurs were tested to failure displacement controlled 3-point bending at a rate of 
0.6 mm/min with a span of 19 mm using a servo-hydraulic mechanical testing system (858 
Mini Bionix II, MTS Corp). Femurs were centrally loaded in the anterior to posterior 
direction. Vertebrae were tested under displacement controlled compression to failure at a 
rate of 0.5 mm/min. Structural properties were calculated directly from the load-
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displacement curve (ultimate load, stiffness, and energy to ultimate load or failure load). 
Derived material properties were calculated from the load-displacement data using 
standard equations (Ultimate stress, elastic modulus, and toughness to ultimate stress or 
failure stress) [171]. All samples were kept moist with PBS throughout testing. 
4.2.5 Statistics 
All data are presented as mean ± SEM. Data from in vivo microCT and serum 
analysis were analyzed using a mixed ANOVA following the general linear model (GLM) 
repeated measures procedure in SPSS (SPSS Statistics 24). Pairwise comparisons were 
adjusted using the Bonferroni correction. Biomechanical properties between WT and HIV 
rats were analyzed using unpaired two-sample Student’s t-test. A significance level of 0.05 
was set for all analyses. 
4.3 Results 
4.3.1 General Observations 
Body weight was significantly different between WT and HIV animals at all ages 
in this study (Figure 4-1). Linear regression analysis revealed that the rate of weight gain 
– defined as the slope (m) of the regression equation (y = b + m*x) – for WT rats was 
significantly greater than HIV rats (WT: m = 7.10 ± 0.66, b = 163.2 ± 5.56, R2 = 0.5431; 
HIV: m = 5.12 ± 0.50, b = 139.5 ± 4.17, R2 = 0.5474; p = 0.019). 
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Figure 4-1. Body mass of WT and HIV rats. n = 11 WT, n = 10 HIV. Error bars indicate 
SEM. * indicates significant difference between groups (p < 0.05). 
4.3.2 Longitudinal Bone Microarchitecture 
In order to evaluate bone microarchitecture changes, microCT scans were 
performed over a period of nine months at three different skeletal sites: femur mid-
diaphysis, distal femur, and L6 vertebra. Femurs were significantly longer in WT animals 
compared to HIV at every time point (Figure 4-2). Evaluations of the cortical bone at the 
femoral mid-diaphysis also showed significantly smaller bones in HIV animals at every 
time point (Figure 4-3). Differences in bone average mineral density were not found. For 
measures with significant differences, linear regression analysis showed no differences in 
the slopes between WT and HIV rats. Despite the greater rate of weight gain in WT 
animals, we do not see a corresponding difference in the rates of cortical bone growth. 
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Figure 4-2. Femur lengths of WT and HIV animals. n = 11 WT, n = 10 HIV. Error bars 
indicate SEM. * indicates significant difference between groups (p < 0.05). 
  

































    
  
Figure 4-3. MicroCT evaluation of cortical bone morphology at the femur mid-diaphysis. 
n = 11 WT, n = 10 HIV. Error bars indicate SEM. * indicates significant difference between 
groups (p < 0.05). Ct.Th = cortical thickness; MOI = moment of inertia; pMOI = polar 
moment of inertia. 
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 The distal femur epiphysis and metaphysis were analyzed separately for trabecular 
bone architecture. Overall evaluation of the data showed that for both groups, the bone 
volume fraction in the femoral epiphysis increased with age from four months to twelve 
months (Figure 4-4). This increase in bone mass is mediated by increases in trabecular 
thickness (Tb.Th) as trabecular number (Tb.N) and spacing (Tb.Sp) appear to remain at a 
constant level. Connectivity density (Conn.D) decreased with age as did SMI values 
suggesting loss of more rod-like trabecular struts in favor of more plate-like trabeculae. At 
the femoral epiphysis, no overall differences between WT and HIV animals in bone mass 
were detected (p = 0.667, BV/TV), but early time point evaluation at four (p = 0.083) and 
five (p = 0.044) months of age suggest there may be differences at earlier ages. While there 
were no differences in trabecular morphology between groups especially with Tb.Th (p = 
0.838), further analysis of Tb.N (p = 0.090), Tb.Sp (p = 0.054), and Conn.D (p = 0.054) 
suggested that HIV animals may have fewer trabeculae (4 months: p =0.044; 6 months: p 
= 0.078; 8 months: p = 0.079; 9 months: p = 0.084) with greater spacing (4 months: p 
=0.029; 5 months: p = 0.083; 6 months: p = 0.027; 8 months: p = 0.041; 9 months: p = 





     
Figure 4-4. MicroCT evaluation of trabecular bone architecture at the distal femur 
epiphysis. n = 11 WT, n = 10 HIV. Error bars indicate SEM. * indicates significant 
difference between groups (p < 0.05). BV/TV = bone volume / total volume, i.e. bone 
volume fraction; Tb.N = trabecular number; Tb.Th = trabecular thickness; Tb.Sp = 
trabecular spacing; Conn.D = connectivity density; SMI = structure model index. 
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 As in the femur epiphysis, general changes in bone for both WT and HIV animals 
in the femur metaphysis consisted of increasing BV/TV, Tb.Th, and mineral density with 
unchanging values for Tb.N and Tb.Sp between four and twelve months of age (Figure 
4-5). An increase in Conn.D was also seen with increasing age for both groups. In contrast 
to the epiphysis, analysis of the distal femur metaphysis revealed significant alterations to 
the morphology of trabeculae in HIV animals. Overall, HIV animals had less bone in the 
metaphysis (p < 0.01, BV/TV) with specific differences at 4, 6, 8, 9, and 10 months of age. 
Similarly, Tb.Th was lower in HIV rats overall (p = 0.004) with significant differences at 
nearly all time points except 7, 11, and 12 months of age. No differences were found in 
Tb.N, Tb.Sp, or bone mineral density, but the trabecular network in HIV animals was 






      
Figure 4-5. MicroCT evaluation of trabecular bone architecture at the distal femur 
metaphysis. n = 11 WT, n = 10 HIV. Error bars indicate SEM. * indicates significant 
difference between groups (p < 0.05). BV/TV = bone volume / total volume, i.e. bone 
volume fraction; Tb.N = trabecular number; Tb.Th = trabecular thickness; Tb.Sp = 
trabecular spacing; Conn.D = connectivity density; SMI = structure model index. 
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 Unlike the changes in the femur, the vertebral trabecular bone structure appears to 
be more stable during this period of growth in the female rat. Both groups had initial 
increases in BV/TV, Tb.N, and Tb.Th and decreases in Tb.Sp and SMI values from four to 
six months of age (Figure 4-6). With the exception of Conn.D, which appears to increase 
then decrease with age, all other measures remain relatively stable from six to twelve 
months of age. When comparing between groups, BV/TV was significantly lower in the 
HIV group (p < 0.001) for all time points except at six (p = 0.056) and seven (p = 0.058) 
months of age. Similarly, Tb.Th values were lower in the HIV group (p < 0.001) for all 
time points except seven (p = 0.209) and eight (p = 0.087) months of age, and SMI values 
were larger in the HIV group (p = 0.001) for all time points except six (p = 0.086) and 
twelve (p = 0.093) months of age. No differences were detected for Tb.N, Tb.Sp, Conn.D 







     
Figure 4-6. MicroCT evaluation of trabecular bone architecture at the L6 vertebra. n = 11 
WT, n = 10 HIV. Error bars indicate SEM. * indicates significant difference between 
groups (p < 0.05). BV/TV = bone volume / total volume, i.e. bone volume fraction; Tb.N 
= trabecular number; Tb.Th = trabecular thickness; Tb.Sp = trabecular spacing; Conn.D = 
connectivity density; SMI = structure model index. 
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4.3.3 Bone Turnover Markers 
Blood was collected from rats at 4, 5, 7, 9, and 11 months of age to evaluate serum 
levels of C-terminal telopeptide (CTx) and osteocalcin, biochemical markers of bone 
resorption and formation, respectively. At five months of age, serum CTx levels in HIV 
animals were on average 13.6% greater than in WT animals (p = 0.07) with a significant 
difference detected at seven months of age (p < 0.01) suggesting a sustained state of bone 
resorption during this time that is not seen in WT animals (Figure 4-7). While no 
differences were found in levels of bone formation between groups, HIV animals had an 
18.9% greater level of osteocalcin on average at 5 months of age. Additionally, both groups 
showed a decrease in bone formation levels from five to seven months of age. 
 
 
Figure 4-7. Bone turnover markers in HIV and WT rats. C-terminal telopeptide (CTx) is a 
marker for bone resorption. Osteocalcin is a marker for bone formation. n = 5-11 WT, n = 
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4.3.4 Bone Biomechanical Phenotype 
Given the significant differences in bone microarchitecture, mechanical testing was 
performed on femurs and L6 vertebrae to assess differences in mechanical strength. HIV 
femurs were found to be mechanically weaker than WT animals (Figure 4-8). Ultimate 
load and stiffness values were lower in HIV femurs but no differences in energy to ultimate 
load were found. Values for derived material properties showed no differences between 
groups suggesting that effects on femur mechanics are driven mainly by structural 
differences. However, in the L6 vertebra, no differences were detected in either measured 







Figure 4-8. Mechanical properties of the femur. (A) Measured structural properties. (B) 
Estimated derived material properties. Error bars indicate SEM. * indicates significant 
difference between groups (p < 0.001). 
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Figure 4-9. Mechanical properties of the L6 vertebra. (A) Measured structural properties. 
(B) Estimated derived material properties. Error bars indicate SEM.  
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Low bone mass and risk for fracture are of critical concern in the HIV-infected 
population that afflicts people of all ages. In this study, we characterized the longitudinal 
skeletal changes in the growing HIV-1 tg rat and assessed alterations to bone 
microarchitecture, bone turnover, and bone biomechanics. Contrary to our initial 
hypothesis, we did not find significant changes in microarchitecture between five and nine 
months of age in the HIV-1 tg rat. In fact, the general growth pattern in the HIV-1 tg rat 
for all bone morphology patterns seemed to follow that of the WT rat with no notable 
exceptions. Even normalizing for differences in body mass maintained significant 
differences in bone mass in the femur mid-diaphysis and L6 vertebra. However, if changes 
in bone morphology were driven by changes in body mass alone, we would expect 
diverging growth rates in various bone microarchitecture measures – especially in cortical 
bone – that follow the differences in weight gain between WT and HIV animals. Although 
we saw significantly sustained serum levels of bone resorption at seven months of age in 
the HIV animals, we did not observe any notable changes in microarchitecture around that 
age compared to WT animals. 
Cortical bone grew with age for all animals and was significantly reduced in HIV 
animals throughout the study supporting the idea that cortical bone of long bones is heavily 
dependent on early life growth and HIV status [87]. However, trabecular bone in the distal 
femur appeared to have more age-dependent changes, increasing in mass via trabecular 
thickness with increasing age. In the epiphyseal region, overall differences were marginal 
for trabecular number and spacing and did not reach statistical significance, but differences 
were found to be significant in the metaphysis for multiple measures of trabecular bone 
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structure. Additionally, trabecular number and spacing were more stable in the epiphysis 
but fluctuated considerably in the metaphysis suggesting active long bone growth 
accentuates the effects on trabecular bone in HIV animals. In contrast, the L6 vertebra was 
markedly more stable in trabecular characteristics over time except for early changes from 
4 to 6 months with more consistent decrements in HIV animals compared to WT animals. 
Interestingly, bone volume fraction did not increase with age after 6 months of age 
supporting the understanding that vertebral growth stabilizes earlier than in long bones 
[197, 200]. Taken together, we have shown that the HIV-1 tg rat presents with age- and 
skeletal-site-dependent differences in bone microarchitecture that may in part be 
determined by early life alterations in bone development. 
Overall, our microarchitecture and bone turnover findings are consistent with 
findings from Vikulina et al. [24]. Interestingly, contrary to our findings, they found no 
differences in cortical thickness between WT and HIV male rats at 8 to 9 months of age, 
and comparison with our study revealed similar average values but less variability in 
female rats. We would expect the male rats to have greater bone size both in terms of HIV 
status but also in comparison to our female rats at the same age [201]. Femurs obtained 
from the Weitzmann group harvested from 14 month old male HIV-1 tg rats were 
qualitatively compared to the 12 month old females from this study. Average cortical 
thickness values were similar as in 8-9 month old rats; however, all cross-sectional area 
measures (i.e., bone area, marrow area, and total area) were greater in the male rats (Table 
B-5). Consequently, MOI and pMOI values were greater in male rats resulting in 
considerably greater mechanical strength of femurs compared to female rats (Figure B-3). 
There were also striking differences in trabecular microarchitecture in male rats at 8-9 
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months old in the distal femur metaphysis that were also found in the female rats but to a 
lesser degree. This suggests that the effects of HIV status on cortical bone may be greater 
in male rats than in female rats. Alternatively, this may be due in part to differences in the 
resolution of scans or may be physiologically due to sex differences in baseline levels of 
bone mass and microarchitecture characteristics. Clinical investigations have shown that 
BMD in HIV positive women decline faster than in men [202], but similar or higher 
fracture rates have been found in HIV-infected men compared with women [132, 203]. In 
addition, men are less likely to be provided proper care for osteoporosis and have greater 
mortality following osteoporotic fracture highlighting the need to consider sex differences 
[204, 205]. Although additional studies are needed to determine if the sex differences in 
the HIV-1 tg rat translate to the clinical setting [121, 126], use of the HIV-1 tg rat may 
prove useful in investigating differential approaches to care based on sex.  
  The rat skeleton continues to grow throughout its lifetime, however peak bone 
mass is considered to be achieved at 10 months of age [197]. The findings here suggest 
that HIV status results in a lower peak bone mass; however, the finding that there were 
significant differences in body mass especially at the earliest age investigated raises the 
question of whether these differences are present at even younger ages. In a separate study, 
we found that HIV-1 tg rats and littermates have similar weights at 3-4 weeks of age with 
significant differences at approximately 4-5 weeks of age (Figure B-4). This is in 
agreement with other studies that showed similar weights between WT and HIV animals 
at early ages [206] that soon diverge as the animals age [21, 198, 207, 208]. Although we 
provided food ad libitum to our animals, another study saw significant differences in 
weight regardless of pair-feeding [21]. As stated earlier, WT rats gain weight at a faster 
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rate than HIV rats, a difference that is not reflected in the rate of change in bone 
microarchitecture. We may therefore offer a hypothesis that early skeletal effects of HIV 
prior to the age studied here in the HIV-1 tg rat lead to a reduced peak bone mass as seen 
in this study. In support of this, results from Yin and colleagues would suggest that 
perinatal and early life HIV infection leads to a below normal peak bone mass [87]. Further 
studies are warranted on prenatal and neonatal animals to determine when significant 
differences in body mass and skeletal development occur and whether these changes are 
what lead to the results presented here.  
Skeletal site-specific changes are also dependent on age in the rat. Growth plates in 
the tibia of female rats close at 14 months of age while in the vertebra, growth plates close 
at 20 months of age [197]. Skeletal growth is also influenced by the transition from 
modeling to remodeling which is associated with very low rates of longitudinal growth. 
This transition occurs in trabecular bone between 6 to 9 months of age at the proximal tibia 
metaphysis and at 3 months of age in the vertebra. The human skeleton however stops 
growing after sexual maturity [32] which occurs in rats at approximately 2.5 months of 
age. This may partially explain the age- and site-related differences seen here that are 
similar to that seen in ovariectomized rats, although the changes due to ovariectomy are 
considerably more pronounced [200]. With osteoporosis in humans, fractures commonly 
occur at the spine, hip, or wrist making these important skeletal sites for investigation of 
bone quality [209]. Clinical studies have assessed bone microarchitecture using HR-pQCT 
and some even implement ITS-based morphological analyses, but this is limited to the 
distal radius and distal tibia [210]. In order to assess trabecular quality at the spine, DXA 
based TBS has been used but this technique does not offer the same granularity that HR-
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pQCT provides [211]. The HIV-1 tg rat model provides an appropriate surrogate with 
which to study age-related and skeletal site-specific changes in bone microarchitecture that 
are challenging in the clinical setting.  
Despite not being directly infected by HIV or hosting active viral replication, the 
HIV-1 tg rat exhibits significant changes to bone microarchitecture and bone turnover 
markers. This suggests there is also an effect of the HIV-1 protein expression that occurs 
constitutively in this model that may be occurring in HIV positive humans on effective 
ART as a consequence of viral reservoirs and low level HIV-1 activity [52, 58, 62]. 
Numerous studies have utilized the HIV-1 tg rat to study HIV associated disorders, and 
this has led to the establishment of this model as effectively reflecting HIV positive 
individuals on effective ART [23, 198]. These rats show localization of HIV-1 proteins 
that are similar to that seen in humans [59, 60, 62]. Additionally, studies of the HIV-1 tg 
rat immune response show differential immune cell responses and cytokine profiles with 
age as well as dysfunctional T cell development and function that are similar to the human 
condition [17, 148, 150, 212, 213]. Most notably, the findings in the HIV-1 tg rat by 
Vikulina et al. were translated to the clinical setting where HIV positive individuals were 
found to have increased bone resorption, low BMD, increased B cell expression of 
RANKL, and decreased B cell expression of OPG [114].  
  As the HIV population continues to grow and age, skeletal health will continue to 
be an area of concern and needed research. Furthermore, understanding how HIV can 
impact achievement of peak bone mass will help inform clinical management of bone care 
in child and adolescent patients infected with HIV. We reported here work towards 
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establishing the HIV-1 tg rat as an appropriate model to study skeletal disorders with 
interest towards HIV associated effects on peak bone mass.  
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CHAPTER 5. BONE HEALING IN HIV-1 TRANSGENIC RAT 
5.1 Introduction 
Bone defects can result from traumatic injury, infection, tumor resection, or fracture 
nonunion [27, 214]. Effective reconstruction of segmental bone defects is an elective 
procedure that continues to be a significant clinical challenge for orthopedic surgeons 
[214]. Clinical management of these defects still results in 5 to 10% progressing to delayed 
union or nonunion [27, 215]. There is concern that the HIV infected population may be 
more susceptible to impaired bone healing [133]. This may be due to low bone mass, a 
dysfunctional immune system, or an imbalance in the remodeling process. However, 
currently there is no consensus in the research literature on whether HIV positive patients 
have greater rates of nonunion [13]. In a prospective study including 36 HIV-positive and 
141 HIV-negative individuals requiring implant surgery, Harrison et al. reported a greater 
proportion of reconstruction for nonunion in the HIV infected group with 14 patients 
identified to have delayed or nonunion [216, 217]. Bahebeck and colleagues reported 
12.3% of HIV infected versus 8.6% of uninfected individuals had mal- or non-union as 
indications for implant surgery [218]. Xu et al. reported a 5.6% prevalence of nonunion in 
their HIV infected cohort compared to 2% in the uninfected controls [219]. In contrast, 
multiple studies reported no cases of nonunion in their HIV infected cohorts [13]. 
Additionally, while closed fractures in the HIV infected population appear to only require 
conventional care, it is not clear whether more complex fractures such as open fractures or 
segmental bone defects require additional interventions and management [13]. 
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Current clinical studies addressing bone healing in the HIV infected population are 
challenged by poor study designs, widely variable demographics, and a greater focus on 
rates of infection [13]. Additionally, clinical assessment of adequate healing of fractures is 
still not standardized, complicating comparisons between studies [13, 140, 220]. Animal 
models thus provide an opportunity to study healing of segmental bone defects with 
significant controls over the variables confounding clinical studies of healing in HIV 
positive patients. There have also been no pre-clinical studies investigating bone healing, 
specifically segmental bone defect healing, utilizing the HIV-1 transgenic rat. 
The HIV-1 tg rat has proven to be useful in the study of HIV associated 
comorbidities [21, 22, 148, 153, 155, 156] including osteoporosis [24, 162]. It has also 
been shown to express HIV-1 viral proteins throughout its life and is considered a model 
for HIV-1 infected individuals on effective suppressive ART [23, 198]. The effects of this 
chronic HIV-1 protein expression on the immune system of the transgenic rat include 
dysregulation of T cells [17, 150, 212, 221], changes to B cell activity [24, 148], and 
alterations to inflammatory response [148, 213]. Given the critical role that the 
inflammatory response plays in repairing bone [37], bone healing in the HIV-1 tg rat may 
therefore be impaired. 
The objective of this work was to investigate the bone healing response in the HIV-
1 tg rat. In order to mimic the clinical situation of a bone segmental defect receiving 
reconstructive care, we utilized a well-established model of a critically-sized long-bone 
segmental defect [222, 223]. To promote healing of the defect, we used a reliable hybrid 
growth factor delivery system consisting of a nanofiber mesh and injectable alginate 
hydrogel loaded with rhBMP-2 that our group has found leads to consistent healing [224, 
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225]. Thus, we sought to determine the bone healing response in the HIV-1 tg rat using a 
segmental bone defect model. We hypothesized that healing in the HIV-1 tg rat would be 
impaired despite the use of a therapeutic intervention. 
5.2 Materials and Methods 
5.2.1 Surgical Procedure 
Female HIV-1 transgenic (tg) (HIV, n = 10) and littermate controls (WT, n = 10) 
were purchased from Harlan Laboratories at 3-4 weeks of age. Animals were maintained 
in sterile caging on a regular light/dark schedule. Food (Teklad Global Diet 2918) and 
water were provided ad libitum. At approximately 9 months of age, all animals underwent 
surgery to create a unilateral critically-sized 8 mm femoral segmental defect as previously 
described [222, 223]. Based on work done in our group showing consistent defect healing, 
defects in this study were treated with 2.5 µg of recombinant human BMP-2 (rhBMP-2; 
Pfizer, Inc.) loaded into a hybrid growth factor delivery system consisting of a nanofiber 
mesh and injectable alginate hydrogel [223]. 
Prior to surgery, one WT animal was found dead at approximately 6 months of age 
with cause of death unknown. Two animals from the HIV group were lost during the study 
due to complications during or after surgery. Three more WT animals were removed from 
the study due to post-surgery complications or they were determined to be statistical 




5.2.2 Radiography and Microcomputed Tomography 
In vivo radiographs (Faxitron MX-20, Digital, Faxitron X-ray Corp) were taken to 
assess qualitative bone regeneration and defect bridging at 2, 4, 8, and 12 weeks post-
surgery. Bridging of the defect area was defined as continuous bone spanning the region 
and was evaluated by two blinded investigators. A third blinded investigator decided any 
instances of disagreement.  
Post-operative in vivo microcomputed tomography (microCT, vivaCT 40, Scanco 
Medical) scans were performed at 4, 8, and 12 weeks to quantitatively assess bone 
regeneration. Animals were anesthetized via isoflurane inhalation for the duration of the 
scan. The scans were performed at a voxel size of 21 µm, energy of 55 kVp, and current of 
145 μA. A consistent volume of interest (VOI) of approximately 5 mm (242 slices) 
encompassing the central region of each defect was analyzed. A threshold corresponding 
to approximately 50% of native cortical bone threshold was applied to segment newly 
formed bone tissue. 
5.2.3 Biomechanical Testing 
Animals were euthanized at 12 weeks post-surgery via CO2 inhalation and femurs 
were harvested, wrapped in saline soaked gauze, and stored at -20°C. Femurs with defects 
were cleaned of all soft tissue and the fixation plate was removed in preparation for 
biomechanical testing. Torsional testing followed previously reported procedures [222]. 
Briefly, femurs were potted into custom made blocks with Wood’s metal (Alfa Aesar) and 
mounted into torsion fixtures on a Bose system (ELF 3220, Bose EnduraTEC). Samples 
were tested to failure under rotation control at 3 degrees per second and rotation and torque 
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data were recorded. Torque-rotation data were analyzed for maximum torque, torsional 
stiffness, and rotation at maximum torque. 
5.2.4 Statistics 
All data are presented as mean ± SEM. MicroCT data were analyzed using a mixed 
ANOVA following the general linear model (GLM) repeated measures procedure in SPSS 
(SPSS Statistics 24). Pairwise comparisons were adjusted using the Bonferroni correction. 
Biomechanical testing data was analyzed using unpaired two-sample Student’s t-test. A 
significance level of 0.05 was set for all analyses. 
5.3 Results 
5.3.1 Segmental Defect Surgery 
A total of 10 animals per group were assigned to undergo unilateral femur 
segmental defect surgery at 9 months of age. A total of four WT and two HIV animals were 
excluded from the study for the following reasons. One WT animal died at nearly 6 months 
of age; no cause of death could be determined by the animal facility veterinarian. Another 
WT animal’s fixation plate was found to be exposed outside of the skin at 8 weeks after 
surgery. The final two WT rats showed no evidence of defect mineralization by 12 weeks 
post-surgery and were identified as statistical outliers. One HIV animal died approximately 
2 days post-surgery possibly due to complications from surgery. An additional HIV animal 
was excluded from the study because it was not possible to properly suture the muscle 
tissue around the defect. The remaining animals (n = 6 WT; n = 8 HIV) were used for the 
remainder of this study.  
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5.3.2 Radiographic and MicroCT Evaluation of Bone Healing 
Two-dimensional radiographs revealed a qualitatively similar bone healing 
response in WT and HIV animals (Figure 5-1). In the WT group, five out of six animals 
had bony bridging by Week 4 with the remaining defect bridged by Week 8. In the HIV 
group, five out of eight animals had evidence of bony bridging by Week 4. The remaining 
three samples were bridged by Week 8. In contrast, quantitative microCT evaluation of 
bone healing showed that HIV animals had impaired healing. At Week 4 post surgery, HIV 
defects had on average 43.1% less mineralized tissue per volume (BV/TV, p = 0.051) with 
significantly lower levels of bone at Week 8 (p < 0.01) and Week 12 (p < 0.01) (Figure 
5-2). Absolute levels of defect bone volume followed a similar pattern of differences. As 
expected, we saw an increase in average mineral density as bone healing progressed, but 
we did not find differences between WT and HIV defects. We analyzed units of 
mineralization as trabeculae and found no differences in mineral number (p = 0.121) or 
mineral thickness (p = 0.236). However, when comparing HIV to WT, we found a 
decreasing difference in mineral number from Week 4 (-32.2%) to Week 8 (-12.9%) to 
Week 12 (-5.6%). In contrast, we found an increasing difference in mineral thickness from 
Week 4 (7.7%) to Week 8 (-11.7%) to Week 12 (-10.8%). Interestingly, we found 
differences between groups in mineral connectivity density (Conn.D) at Week 4 (p = 0.048) 
and Week 8 (p = 0.029) but not at Week 12. 
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Figure 5-2. MicroCT analysis of bone healing response. (A) Representative Week 12 ex 
vivo 3-D reconstructions of defect area. Cortical bone ends have been included for 
orientation. (B) Longitudinal evaluation of new bone growth. n = 6 WT; n = 8 HIV. Error 
bars indicate SEM. Scale = 1 mm. * indicates significant difference between groups (p < 
0.05). 
WT HIV
350    [mg-HA/cm3]     850



















@ 4 : p  =  0 .0 5 1
























@ 4 : p  =  0 .0 5 1
*
*


























@ 4 : p  =  0 .0 2 1





























@ 8 : p  =  0 .0 9 9




























































































































5.3.3 Biomechanical Testing 
We next performed biomechanical testing to assess the functional restoration of 
bone mechanical properties. No differences in maximum torque (-69.9%, p = 0.18) or 
torsional stiffness (-48.4%, p = 0.059) were found when comparing HIV to WT groups.  
We further asked if there was a relationship between the microCT measures and the 
observed biomechanical properties. Ex vivo Week 12 microCT values were compared with 
maximum torque and torsional stiffness (Table 5-1). Overall correlations showed a strong 
relationship between maximum torque and bone volume (BV), bone volume fraction 
(BV/TV), and mineral connectivity density (Conn.D). When the correlations were 
calculated for each group, no significance was found with the WT animals. However 
significant correlations between BV, BV/TV, and Conn.D with maximum torque were 
found in the HIV group with BV and Conn.D combined being the best predictors of 
maximum torque. Interestingly, a significant correlation between total volume (TV) and 
torsional stiffness was found which remained significant after subtracting out the bone 
volume. This suggests that the soft tissue within the defect contributes significantly to 
torsional stiffness in HIV animals. 
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Figure 5-3. Biomechanical properties of bone defects. n = 6 WT; n = 8 HIV. Error bars 
indicate SEM. * indicates significant difference between groups (p < 0.05). 
Table 5-1. Pearson's Correlation Coefficient (r) between biomechanical properties and 
microCT measures (n = 5 WT, n = 8 HIV). 
Overall 
 TV BV (TV-BV) BV/TV Conn.D Mineral Density 
Maximum Torque 0.079 0.745** -0.086 0.673* 0.644* -0.163 
Torsional Stiffness 0.432 0.395 0.352 0.150 0.325 -0.145 
WT 
 TV BV (TV-BV) BV/TV Conn.D Mineral Density 
Maximum Torque 0.056 0.002 -0.159 -0.048 0.217 -0.030 
Torsional Stiffness 0.028 -0.205 -0.078 -0.19 0.193 -0.164 
HIV 
 TV BV (TV-BV) BV/TV Conn.D Mineral Density 
Maximum Torque 0.190 0.893** 0.057 0.813* 0.745* -0.011 
Torsional Stiffness 0.773* 0.451 0.754* -0.188 -0.105 0.501 
* p < 0.05       
** p < 0.01       
TV = Total Defect Volume; BV = Bone Volume; (TV-BV) = Soft tissue volume; BV/TV = Bone 
volume fraction; Conn.D = Connectivity Density 
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5.4 Discussion 
In this study, we investigated the bone healing process in the HIV-1 tg rat using an 
established critically-sized long-bone segmental defect model. Confirming our hypothesis, 
the HIV-1 tg animals had less mineralized tissue at every time point after surgery. The 
characteristic of the mineral units provided more information, revealing that while the 
thickness increased over time and tended to be greater in the WT animals over time, the 
absolute difference between groups in number of mineral units decreased as the HIV group 
reached a similar number by Week 12. These findings combined with the initial greater 
connectivity in WT animals suggests that the bone healing response in HIV animals is 
impaired as early as Week 4, forming fewer, less connected but similarly thick mineral 
units that eventually increase in number and thicken but remodel to a network of newly 
formed bone. Contrary to the microCT findings, we were unable to detect differences in 
defect mechanical properties. These results are consistent with our pilot data utilizing 
bilateral segmental defects and present the first pre-clinical evidence for impaired bone 
healing in the HIV-1 transgenic rat despite therapeutic intervention. This impairment may 
be mediated by a decrease or a delay in mineralization but further studies are needed to 
investigate this. 
  Fracture healing in the HIV infected population has long been suspected to be 
negatively impacted due to the effects of HIV on bone mass, bone turnover, and the 
immune system [133]. In Chapter 4, we showed that the HIV-1 tg rat has decreased bone 
mass at 9 months as measured in cortical bone at the femur middiaphysis, and in trabecular 
bone at the femur distal metaphysis and L6 vertebra. However, the amount of bone present 
is more associated with the risk for fragility fractures – not a natural occurrence in rodents 
 92 
[226] – and in terms of bone healing, risk for failure of fracture fixation [227]. 
Qualitatively, we did not find any loosening or loss of stability of our fixation plates in the 
HIV animals nor did we observe any differences in screw removal difficulty from WT or 
HIV bone when preparing for mechanical testing. This is further supported by the findings 
in Chapter 4 that no differences in bone mineral density were present between groups 
suggesting that, at least for the cortical bone of the femur, the decreased amount of bone 
does not impact implant stability in the HIV-1 tg rat. Whether this is the case in trabecular 
bone remains to be investigated. Current clinical findings would suggest that failure of 
fracture fixation is not a cause for concern [13], but given the inherent variability in 
studying fracture healing especially in the HIV population, further studies are needed to 
address this issue.  
 Based on results from Chapter 4, WT and HIV rats may have similar global levels 
of bone turnover markers by the time of surgery at 9 months of age. However, there may 
be local differences in bone formation and resorption. Multiple in vitro studies have 
suggested a detrimental effect of HIV on osteoblast precursors [105, 108-112] and 
osteoblast activity [104-107]. In line with these findings, our bone healing results in HIV 
animals are suggestive of impaired mineralization specifically reflected in the relative 
changes in mineral unit thickness. Although the HIV-1 tg rat has a more pro-
osteoclastogenic bone marrow environment [24], this may not result in increased resorption 
in our model of bone healing. Looking at the changes over time in connectivity and number 
of mineral units suggests a similar healing process that is attenuated in the HIV animals. 
Additionally, the differences in new mineralized tissue are apparent as early as 4 weeks 
after bone injury. This would suggest that there is not a difference in resorption activity 
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between groups within the period of bone healing studied here but perhaps an early and 
continued suppression of bone formation. Since our segmental defect model is critically-
sized and does not heal spontaneously without intervention, we utilized a hybrid growth 
factor delivery system consisting of a nanofiber mesh and injectable alginate hydrogel 
loaded with rhBMP-2 to induce bone healing. BMP-2 promotes chondrogenic and 
osteogenic differentiation early in the inflammatory phase of fracture healing [38, 228], 
and it was shown in our model that over 90% of the dose of BMP-2 delivered to the defect 
area is cleared by 21 days [229]. This suggests that the HIV animals in this study may have 
less sensitivity to BMP-2 osteoinductive effects and further supports the notion that the 
HIV-1 tg rat has an impairment of bone healing via attenuation of bone formation.  
 Fracture healing in the context of osteoporosis is generally characterized by a 
delayed healing response [134]. While an imbalance of bone resorption and formation 
seems to characterize bone loss in HIV patients as with primary osteoporosis, the 
mechanism behind this disruption with HIV appears to be driven by direct effects of HIV 
infection, HIV viral products, and ART on the immune system leading to an increase in 
bone resorption [113, 230]. Specifically, T and B lymphocytes have been found to be key 
mediators in the fracture healing process [135-138] and have been shown in the HIV-1 tg 
rat to be negatively impacted [17, 24, 148, 150, 212, 221] resulting in alterations to 
inflammatory response [148, 213]. Interestingly, pro-inflammatory cytokines are increased 
in HIV-1 tg rats suggestive of a systemic chronic inflammatory state that may have a 
negative impact on bone healing [37, 139]. The complex interplay between immune cells, 
inflammatory cytokines, HIV gene expression, and bone healing has been poorly studied 
and warrants further investigation. 
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 There are notable differences between our study and previous studies from our 
group [223, 229]. The choice of a 2.5 µg dose of rhBMP-2 was motivated by the consistent 
bridging seen in 2-D radiographs from previous work. Although we likewise found 
complete bridging by 12 weeks post-surgery, the resulting amount of tissue mineralization 
(i.e., bone volume) seen via microCT analysis was noticeably lower, reflecting values seen 
at a BMP-2 dose of 1 and 2.5 µg at 8 weeks post-surgery [229]. Biomechanical properties 
of the healed defect were similar to results seen from defects treated with 0.5 and 1 µg 
BMP-2. While this work utilized rats on an F344/NHsd inbred background and the 
previous work was conducted in SASCO Sprague Dawley outbred rats, the greater cause 
for discrepancy may be in the age of animals at surgery. Owing to the reported onset of 
HIV/AIDS clinical symptoms between 5 and 9 months of age, surgeries in this study were 
performed on animals at 9 months of age whereas rats at 13 weeks of age underwent 
surgery in our previous studies. Aging is associated with a pro-inflammatory state and via 
multiple factors, may impair bone healing [231-233]. In particular, older rats have delayed 
healing [234-236] and have different gene expression in the fracture callus than younger 
rats with a notable decrease in BMP-2 expression [237, 238]. How bone healing varies 
with age in this model requires further study, especially to determine if this segmental 
defect model eventually heals to a mechanically competent level in both WT and HIV rats.  
 This study had several important limitations. Animals used in this study were age-
matched but not weight-matched. However, given the considerable variability in age that 
would occur with weight-matching and the significant age-related effects on bone healing, 
animals were age-matched for this study. Other studies utilizing the HIV-1 tg rat have also 
seen weight differences between WT and HIV animals [21, 24, 198] but the mechanism 
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for this is unknown and may be a consequence of HIV effects on multiple organ systems. 
Our study also did not investigate healing time points prior to 4 weeks or beyond 12 weeks 
post-surgery. Although we found significant differences in healing between groups in our 
study, further investigation into the progression of bone healing, specifically early 
inflammation and functional recovery of bone tissue, are needed to fully understand bone 
healing in the HIV-1 tg rat model. Finally, previous work from our group has shown that 
the alginate gel in our delivery system remains in the defect area up to 30 weeks post-
surgery and, although bone is remodeled to a lamellar structure and the regenerated tissue 
provides sufficient mechanical strength for ambulation, may interfere with secondary bone 
remodeling as the bone is not restored to a cortical bone architecture. 
 Effective care and management of segmental bone defects remain a significant 
challenge for orthopedic surgeons. As the HIV infected population grows and ages, 
presentation of a segmental bone defect in an HIV positive patient may become more 
common. Additionally, in the United States, HIV testing is not mandated, and 15% of those 
infected with HIV are not aware of their HIV status [49]. Increasing understanding of bone 
healing in the context of HIV may provide healthcare providers with additional criteria by 
which appropriate care can be provided. We reported here work towards furthering this 
understanding as well as establishing the HIV-1 tg rat as an appropriate model to study 
bone healing and more specifically critically-sized bone defects that require intervention 
to achieve functional restoration of bone. This work further emphasizes the need to 
investigate the negative impact HIV infection may have on bone healing outcomes. 
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CHAPTER 6. SUMMARY AND FUTURE DIRECTIONS 
6.1 Overall Summary 
The HIV infected population is a growing and aging demographic that requires 
unique healthcare considerations. Current understanding of the complex relationship 
between HIV and bone remains incomplete. Animal models allow for significant 
investigations into diseases and therapies that would be prohibitive with humans. Although 
there exist animal models of HIV/AIDS, they are primarily used for cure research and 
require significant resources for study. The HIV-1 tg rodent models provide decreased 
barriers to conducting research with specific regard to the study of skeletal disorders in 
HIV infected individuals on effective viral suppression treatment. 
It is widely accepted in the literature that individuals infected with HIV – both with 
and without ART – are at a greater risk for osteoporosis and fracture. Aside from the study 
showing that the HIV-1 tg male rat mimics an osteoporotic phenotype [24], limited studies 
have addressed bone-relevant dysfunction in the HIV-1 tg rodent models with no studies 
addressing effects on bone biomechanical properties or bone healing. Additionally, there 
is no reported data on the HIV-1 tg female rat regarding skeletal defects nor has the skeleton 
of the HIV-1 tg mouse been characterized for bone microarchitecture or bone healing. 
Therefore, the overall objective of this work was to investigate the effects of HIV on 
skeletal growth and bone healing as exhibited by two noninfectious HIV-1 transgenic 
rodent models, specifically the mouse and the rat. The central hypothesis of this project 
was that HIV-1 transgenic animals will present with significant deficiencies in skeletal 
development and bone repair. 
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To test this hypothesis, we explored the skeletal phenotype, bone mechanics, and 
bone healing of the HIV-1 tg mouse and rat models. First, utilizing the HIV-1 tg mouse 
model, we studied bone microarchitecture and biomechanics for the femur and L6 vertebra 
at 10-12 weeks of age (Aim I, Chapter 3). This was followed by an investigation into the 
fracture healing process utilizing a closed femur fracture with intramedullary pin 
stabilization. HIV mice had significant decrements in bone microarchitecture at all skeletal 
sites studied accompanied by a reduction in structural mechanical properties in the femur 
and L6 vertebra. Fracture healing in the HIV-1 tg mouse was found to be significantly 
impaired by four weeks post injury resulting in a significant loss of mechanical properties. 
Second, we characterized the longitudinal skeletal growth of the HIV-1 tg rat and assessed 
whole bone mechanics at twelve months of age (Aim II, Chapter 4). Overall, HIV-1 tg rats 
did not show a significant characteristic change between five and nine months of age. 
However, we did find significant deficits in bone mass and microarchitecture in both 
cortical and trabecular bone in the HIV rats compared to WT rats throughout the study. 
This was accompanied by a reduction in femoral but not vertebral biomechanics. Finally, 
we investigated the bone healing process in the HIV-1 tg rat using a critically-sized bone 
segmental defect (Aim III, Chapter 5). The HIV group had an impaired healing response 
characterized by lower bone volume and decreased mineral characteristics that led to 
nonsignificant reductions in average biomechanical measures. Collectively, the findings 
from this thesis provide evidence for a potential negative effect on bone structure and 
function that may be independent of HIV infection or ART and directly or indirectly related 
to HIV-1 protein expression as presented by the HIV-1 tg rodent models. Notably, this 
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work presents the first pre-clinical evidence for impaired bone healing in HIV-1 transgenic 
rodents. 
6.2 Skeletal Development and HIV 
The results from the skeletal phenotype studies in both the mouse and rat showed 
significant decrements to cortical and trabecular morphology generally consistent with that 
reported in the HIV positive population. There were however differences between the two 
models and skeletal site-specific differences. Notably for cortical bone, cortical total area 
was not different in mice, but was different in rats while all other cortical morphology 
measures were different between WT and HIV groups in mice and rats, respectively. For 
trabecular bone, differences in the distal femur metaphysis and L6 vertebra were similar 
between mice and rats but measures at the distal femur epiphysis were not; in mice, we 
found significant differences between WT and HIV groups that were not mirrored in rats. 
The discrepancies between these models may be a consequence of differences in 
experimental design, species skeletal characteristics, and HIV gene expression.  
Although we can estimate the age of rodents in terms of human years based on 
different growth periods [239, 240], this comparison is still an approximation of 
development and aging. However, it provides us with information to make general 
comparisons between pre-clinical rodent models that can then be translated to human 
studies. Bones from mice were studied ex vivo at 10-12 weeks of age, falling short of the 
average time of skeletal maturity of 4 months [172] while rat bones were studied in vivo 
across multiple ages including the time of skeletal maturity at 10 months of age [197]. We 
can roughly estimate that 10-12 weeks of age in the mouse is approximately 25-30 weeks 
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(or 6.25 to 7.5 months) of age in the rat by using the age of skeletal maturity as the 
reference. Comparing results at these ages suggests that more differences between WT and 
HIV may have been found in the rat, especially in the distal femur epiphysis. Nevertheless, 
in order to make adequate comparisons between HIV-1 tg mice and rats would require a 
similar longitudinal study in the mouse such that relative changes in bone microarchitecture 
can be compared.  
Furthermore, skeletal growth and aging effects vary by species and sex at different 
skeletal sites. While both species continue to grow after sexual maturity, loss of both 
cortical and trabecular bone in mice is remarkably similar to that seen in humans, beginning 
after peak bone mass is attained and the majority of bone loss occurring by 6 months of 
age [172]. In rats, loss of bone does not occur with age but does slow appreciably and 
transitions from bone modeling to remodeling at different skeletal sites and at different 
ages [32]. To match more closely the loss of bone seen in humans, models of osteoporosis 
have been developed in both mice and rats. The various approaches to inducing loss of 
bone in rats have proven to closely mimic osteoporosis in humans and thus bypasses the 
challenge of a lack of age-related bone loss in these animals [197]. Sex differences between 
mice and rats are similar with females having smaller bones that undergo greater losses to 
bone mass or mechanics compared with males [173, 201]. In support of this, in Chapter 4 
we discussed the differences between the microarchitecture and biomechanics in HIV-1 tg 
female and male rats. Our findings suggested that HIV effects may be more detrimental in 
males than in females or that baseline sex differences in bone highlight the negative effect 
in males more than in females. These sex differences are seen in humans as well with 
women generally having less bone and losing bone faster with age [202, 204] while 
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fractures at osteoporotic sites occur at similar or higher rates in men [132, 203]. Despite 
these species and sex differences, our work has shown that there is an overall similar loss 
of bone in both mouse and rat models that results in an HIV skeletal phenotype similar to 
that reported in the HIV positive population. Future work could use the HIV-1 tg rodent 
models to study site-specific and sex-dependent changes in bone microarchitecture with 
age and with an induced osteoporotic phenotype. Further work could then investigate the 
complex combination of HIV, osteoporosis, and various interventions for recovering bone 
such as antiresorptive drugs, diet and supplementation, sex steroids, and physical activity. 
Importantly, the expression of HIV genes is variable with age and between HIV-1 
tg mice and rats. Mice have high expression of HIV proteins in the skin, muscle, and tail 
but low expression in the thymus, a critical organ in the immune system especially for T 
cell development [174]. They have primarily been shown to present with renal disease [16, 
20] and cardiovascular dysfunction [18, 19]. Rats have likewise been reported to present 
with HIV/AIDS symptoms including skin lesions, wasting, and muscle atrophy, but more 
importantly efficiently express proteins in the liver, kidney, and essential lymphoid tissues 
including the spleen, thymus, lymph nodes, and blood [17, 21, 144]. They have been used 
to investigate a multitude of disorders associated with HIV [21, 22, 24, 144, 151-158]. 
Each model offers its own unique advantages and disadvantages when it comes to studying 
HIV associated disorders. Mouse models in general offer greater opportunities for genetic 
modification. Our work here utilized mice on both the FVB/N and C57BL/6 backgrounds 
and given the differences in skeletal phenotypes [187, 188] and severity of disease 
presentation, there may be interesting genetic contributions to these differences. 
Additionally, gene specific transgenic HIV-1 mice have been created that have allowed for 
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study of specific protein effects [159, 175-177]. The HIV-1 tg rat model has been studied 
considerably more owing to the more efficient expression of HIV-1 genes and has thus 
been characterized more heavily especially in the study of neurocognitive disorders [23, 
155]. Coupled with their added size, rats allow for more clinically relevant investigations 
especially of effects in HIV infected individuals on effective ART [144, 148, 198]. In spite 
of the differences between the mouse and rat, we found similar deficits in bone 
microarchitecture and biomechanics suggestive of an HIV phenotype that may be HIV-1 
protein specific. Future work could investigate the localization of HIV-1 gene expression 
in different bones, in bone marrow, and in bone cells and how this might be related to 
differences in bone microarchitecture. Additionally, protein specific effects could be 
investigated via genetic modification or via direct injection of HIV viral products. 
Interestingly, there may be a similar disruption to immune function specifically a 
dysfunction of T cells and B cells in both mice [146, 147, 177] and rats [17, 24, 148, 150] 
perhaps suggestive of a chronic immune activation state in both models [241, 242]. It has 
been suggested that in humans, HIV reservoirs – replication-competent, transcription-
competent, and translation-competent – and so-called “defective” proviruses may in part 
be responsible for this chronic immune activation [62, 243, 244] and thus low bone mass 
and increased fracture risk in HIV infected individuals [230]. As researchers gain further 
understanding of the role of HIV reservoirs and viral products in the HIV infected 
population, the HIV-1 tg rodent models may prove useful in studying tissue- and age-
specific effects of HIV proteins especially as it relates to skeletal disorders. 
Peak bone mass is of critical concern for perinatally HIV infected individuals or 
those infected at a young age [85, 87, 192]. Both mice and rats can be used to study effects 
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on peak bone mass as alluded to earlier, and in our work, we studied mice and rats near 
their respective age of skeletal maturity. We found that HIV animals had lower bone mass 
and significant decrements to bone microarchitecture. Based on the longitudinal data in the 
rats, these differences may be a consequence of early developmental effects of HIV. In a 
study looking at early development of chronic neurological impairment, HIV-1 tg rats had 
similar weights but opened their eyes later – indicative of selective somatic growth – as 
measured before postnatal day 21 and were also found to have alterations in early 
locomotor activity [206]. Significant effects of HIV gene expression may similarly occur 
with skeletal development in both the HIV-1 tg mouse and rat either prenatally or 
postnatally. In fact, maternal HIV infection is associated with a higher risk of preterm birth, 
low birth weight, and small-for-gestational-age whether the mother is ART-naïve or not 
[80, 81] suggesting negative effects on skeletal health may begin in utero. Further 
investigation could study these early effects on the skeleton using the HIV-1 tg rodent 
models by looking at both genetic and mechanical effects on embryonic skeletal 
development [245]. 
Our work here presented that HIV bone biomechanics showed reductions to 
structural mechanical properties but not to derived material properties. This is in agreement 
with Yin et al. who used microFEA and found a reduction in stiffness in bone from the 
distal tibia and distal radius of young men infected with HIV [87] and with Springer et al. 
who, in a humanized mouse infected with HIV, determined that femurs had lower hardness 
and tibiae had lower ultimate load and stiffness values compared with controls [161]. 
However, contrary to our findings, Guerri-Fernandez and colleagues used 
microindentation at the midpoint of the midshaft anterior tibial plateau and found decreased 
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bone material properties in HIV patients, especially women, that was independent of BMD 
and ART [131]. It may be that there were differences in material properties that we were 
unable to detect in this study. Specifically, we did not investigate in depth the tissue level 
material properties of bone and relied on common equations derived from beam theory for 
estimating these values [171]. Further studies are needed to determine if there are 
differences beyond the structural mechanical property differences we found here. 
 
6.3 Bone Healing and HIV 
In both HIV-1 transgenic rodent models, we showed impairment of bone healing 
as reflected by reductions in bone formation and a failure to recover functional bone 
mechanics. We simulated a closed fracture in the mouse femur by creating a small 
osteotomy followed by fracture reduction and stabilization via an intramedullary pin. This 
model closely mimics the clinical use of intramedullary rods or nails to internally stabilize 
a long bone fracture [246]. In the rat, we simulated a challenging bone segmental defect 
under reconstructive care by creating a critically-sized 8 mm mid-femur defect with plate 
stabilization treated with a hybrid growth factor delivery system. The standard of care for 
bone defects continues to be the use of autologous bone grafts [214], and while our model 
uses a pre-clinically established therapeutic intervention, the challenge to bone healing 
remains relevant. The bone injuries and management in the mouse and rat were 
considerably different and yet the disparity in healing response between WT and HIV 
animals was remarkably similar. At early time points corresponding to late stage soft callus 
establishment and early mineralization, we found no statistical differences in the volume 
of newly mineralized tissue between WT and HIV groups. At later time points at which 
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most of the mineralized cartilage matrix has been replaced by woven bone and coupled 
remodeling is underway, we saw significantly lower amounts of bone in HIV animals. The 
association between HIV and increased osteoclastogenesis [99-101] and osteoclast activity 
[24, 102, 103] suggested that perhaps resorption would be increased in the HIV animals at 
the relevant phases of bone healing. Looking at the volume of bone formed, the absolute 
difference between WT and HIV animals increased with time suggesting attenuated bone 
formation or increased bone resorption or a combination of the two in the respective HIV 
groups. In the rats, however, we saw differences in mineralized tissue connectivity at 4 and 
8 weeks after surgery but this difference was not seen at 12 weeks. In mice, we saw a 
reduction in absolute difference in total callus volume to similar values at 4 weeks post 
fracture. Both of these findings suggest a resorption response that is proportional to the 
callus and mineralized tissue formed that ultimately results in a similar nominal level of 
tissue size and characteristics. Thus, the resulting differences in newly formed bone and 
tissue mechanics may be a consequence of attenuated bone formation. 
In support of this, several in vitro studies have been performed to study the effects 
of HIV-1 and its proteins on osteoblast precursors and osteoblasts. These effects on 
mesenchymal stem cells include early senescence, decreased proliferative capacity, 
decreased osteogenic potential, and increased adipogenic potential [105, 108-112] 
suggesting that even in the presence of the osteoinductive protein BMP-2, the level of bone 
formation will be decreased in HIV-1 tg rodents. Osteoblasts likewise have negative effects 
on their activity including decreased calcium deposition, decreased alkaline phosphatase 
(ALP) activity, reduced proliferation, and increased apoptosis [104, 105, 107]. Further 
work is needed in order to determine if the cells from the HIV-1 tg rodent models have a 
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similar dysfunction and to what extent they express HIV-1 proteins within these cells. 
Future work could look at specific protein effects on bone healing either by studying 
whether HIV proteins localize in the bone injury site or through genetic modification to 
isolate viral gene products. Additionally, direct injection of HIV-1 proteins into the bone 
injury site of normal non-HIV animals could provide an easier method for determining 
specific protein effects. This could also be accomplished by loading HIV-1 proteins into 
the nanofiber mesh and hydrogel growth factor delivery system. 
As mentioned earlier, both HIV-1 tg mice and rats have differentially altered 
immune systems characterized partially by dysfunctional T and B lymphocytes. Both cell 
types have been shown to be intricately involved in the bone healing response mediating 
and coordinating both bone formation and resorption processes [37, 113, 135]. These cells 
are present at all stages of the bone healing process except during much of the soft callus 
stage of cartilage formation [138]. Interestingly, the absence of T and B cells results in 
enhanced fracture healing characterized by earlier mineralization and gain in mechanical 
strength [136]. However, this expedited mineralization is at the expense of building quality 
bone with adequate elastic properties for restoration of functional mechanics [137]. The 
HIV-1 tg rodent models have an intact adaptive immune system, so the apparent 
attenuation of bone formation in the healing process may be due in part to dysfunctional T 
and B cells. Future work in these models could investigate the spatiotemporal presence of 
T and B cells in and around the bone injury as well as the levels of different inflammatory 
cytokines to determine how the inflammatory response and more generally the immune 
system affect bone healing. 
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As previously discussed, we utilized two different models of bone healing. 
Additionally, the animal characteristics (i.e., species, age, and sex) were not similar across 
the healing studies. Regardless of these differences, we still found a significant detriment 
to bone healing mediated by either a decrease or delay in mineralization that was associated 
with the HIV status of the animal. There are a multitude of opportunities for studying bone 
healing utilizing the HIV-1 tg rodent models. In addition to the closed fracture and 
segmental defect models, there is also a need to study delayed union and nonunion in the 
context of HIV that may be met by small animal models [247]. In low-income countries, 
non-operative management is still widely used making delayed union and nonunion 
common indications for surgery [246]. Although clinical findings suggest no complications 
from reconstructive surgery in the HIV positive population, recovery may be delayed or 
the quality of healed bone tissue may be suboptimal. Given the significant impact and 
incidence of fractures in the young population in low- and middle-income countries [248, 
249] and the growing population of aging HIV infected individuals, the HIV-1 tg rodent 
models provide avenues for addressing the possible age-related differences in bone healing. 
In particular, age-related loss of bone due to sex-specific osteoporosis can be studied using 
these HIV animals and either ovariectomy or orchidectomy. 
6.4 Bone, ART, and HIV 
Although it has been shown that HIV infection alone is associated with bone loss, 
the introduction of ART and subsequent improvement in life expectancy has created an 
increasingly complex situation for healthcare providers. Understanding the milieu of 
factors affecting the HIV positive patient will be critical for providing appropriate care. 
Investigating ART effects on bone in animals may not prove to be fruitful due to the fact 
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that these animals are not infected by HIV and the mechanisms by which ART influences 
bone mass and microstructure is indirectly through the immune system. Results from 
microCT analysis and biomechanical testing of bones obtained from FVB/N mice 
administered azidothymidine (AZT) via oral gavage at 100 mg/kg/day from a previous 
study [18, 250] showed no differences compared to mice administered water (Table B-4, 
Figure B-1, Figure B-2). This is in contrast to Pan and colleagues who showed that mice 
given AZT orally have decreased BMD compared to mice given water only [251]. Given 
that the effects of ART on bone may be driven by immune reconstitution and that rodents 
are not capable of being infected by HIV, the HIV-1 tg rodent models may not be useful 
for studying direct ART effects on bone. However, they may still prove useful for use in 
studies regarding ART toxicity or polypharmacy or for effects of immune reconstitution 
[116, 252]. 
Nevertheless, given that the HIV-1 transgenic mouse and rat models have been 
shown to mimic specific HIV-1 associated comorbid conditions seen in humans infected 
with HIV, these transgenic animals are considered to be appropriate models for studying 
the chronic conditions that present in HIV infected individuals on effective suppressive 
ART [23, 144, 198]. Additionally, as discussed earlier, these HIV-associated comorbidities 
may be partly a consequence of chronic immune activation stemming from various viral 
products from HIV reservoirs. The HIV-1 tg rodent models may thus be useful in 
understanding how the localization of viral products and HIV-1 protein toxicity affects 
bone tissue and bone cells. 
6.5 Final Conclusions  
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The population living with HIV infection is growing and aging, a reality that will 
require significant research if this group is to be provided effective healthcare. It has been 
well established that HIV positive individuals are at an increased risk for osteoporosis and 
fragility fractures and alarmingly at a younger age. This thesis presents work towards 
supporting the utilizing of the HIV-1 transgenic mouse and rat models for studying skeletal 
disorders with specific attention to age-related changes to bone microarchitecture and 
biomechanics and bone healing. Our results show similar detriment to cortical and 
trabecular bone architecture seen in HIV patients with low bone mass. Additionally, we 
present whole bone mechanics that reflect a decrease in mechanical competency driven by 
changes in bone microarchitecture. Finally, we present for the first time pre-clinical 
evidence for impaired bone healing using two different models of bone injury. Further 
investigations using these models will help elucidate the complex relationship between 
HIV and bone dysfunction and promote continued use of animal models for the study of 
HIV associated diseases. 
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APPENDIX A.  PROTOCOLS 
A.1 Mouse Fracture Surgery Protocol 
Protocol for the placement of the support pin and formation of a transverse femur fracture 
(adapted from Craig Duvall; Doctoral Thesis 2007; Georgia Tech) 
Instrument and Materials List 
1. Animal Prep: 
- Isoflurane 
- Ocular lubricant 
- 2x2 gauze 
- Alcohol  
- Chlorhexidine Solution 
- Scrub solution  
- Cotton tip applicator 
- Nair 
- 23g needles 
- 1 mL syringe 
- Buprenorphine 
2. Surgery: 
- Sterile gloves (x2 pairs per animal) 
- Sterile drapes (at least 2 + 1 per animal) 
- Large scissors (x2) 
- Sterile 2x2 gauze 
- Pick-up Forceps with teeth (x3) 
- Forceps with teeth (x3) 
- Small scissors (x2) 
- Small curved tip forceps with teeth (x3) 
- #7 scalpel handle (x2) 
- #15 scalpel blades (at least 1x per animal) 
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- 25g needles (at least 1x per animal) 
- K-wire cutters 
- Needle drivers (x2) 
- Gigli wire saw: ~8 in. lengths (1x per animal) 
- Curve tip hemostats (x3) 
- 5-0 sutures 
- 7mm wound clips (at least 1x pack per 3 animals) 
- 7mm wound clip applier 
- Sterile stainless steel bowl 
- Sterile saline for washing instruments 




- Container to mix in 
Procedure 
1. Instruments will be autoclaved prior to surgery. In between surgeries, instruments 
will be sterilized with glass bead sterilizer. Only the tips of the instruments and 
not the handles will be sterilized. 
2. Mouse will be anesthetized using isoflurane administered at 3% for induction and 
1.5% for maintenance. Depth of anesthesia will be monitored via toe withdrawal 
response. 
3. Lateral right side of animals will be shaved from knee up 
4. Remainder of hair in this region will be removed with depilatory cream (Nair) 
5. The skin will be cleaned with water to remove excess cream and hair and then the 
skin will be cleaned and prepared for surgery (scrub, alcohol rinse, and 
chlorhexaderm) 
6. Longitudinal skin incision will be made along lateral side of leg from knee 
towards hip 
7. A longitudinal cut along the lateral condyle of the femur will be made using a No. 
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15 scalpel 
8. The biceps femoris and vastuslateralis muscles will be teased apart to expose the 
lateral side of the femur 
9. The patella will be slid to the medial side of the condyle 
10. The condyle will be exposed by flexing the knee and a 25-gauge needle will be 
inserted into the intramedullary canal to create a “pilot hole” 
11. Using the trocar end of a K-wire (KI-71-100, Key Surgical) cut in half, the K-wire 
will be inserted into the intramedullary canal following the “pilot hole” 
12. Then, using the 0.22 mm gigli wire saw cut to a length of approximately 8 inches, 
the gigli wire will be fed under the medial side of the femur and pulled up the 
anterior side of the femur 
13. With an assistant stabilizing the pin and limb, the gigli wire will be used to saw a 
mid-diaphyseal transverse osteotomy 
14. Any connected cortical bone on the lateral side of the femur will be cut using the 
No. 15 scalpel 
15. The K-wire will be slid slightly back out of the intramedullary canal of the femur, 
and the needle will be cut to the appropriate length (so that the intramedullary 
support is flush with the surface of the condyle at the needle insertion point). 
16. The patella will be slid back into its native position, covering the condyle. 
17. Using 5-0 absorbable sutures, one suture will be placed to hold the biceps femoris 
and vastuslateralis muscles together. 
18. One suture will be placed to connect the patellar ligament to the adjacent 
musculature on the lateral side (to keep the patella from sliding back out of place). 
19. The skin incision will be closed using interrupted sutures and staples. 
20. The animal will be allowed to awaken from anesthesia on a heating pad. 
21. The animal will be allowed to ambulate freely upon awakening. 
22. Staples will be removed after 7-9 days. 
23. All animals will receive sustained released Buprenorphine (Bup SR) immediately 
prior to surgery at a dose of 1.0 mg/kg. 
24. Postoperatively, animals will be observed for signs that are suggestive of distress 
(e.g., decreased activity levels, poor grooming, hunched posture, etc.).  
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A.2 Rat Tail Ventral Artery Blood Collection and Serum Isolation Protocol 
I. Fasting 
a.  6 hours MINIMUM before collecting blood (RatLaps EIA) 
II. Room Preparation (record time in) 
a. Set up anesthesia (2 separate stations) 
i. For multiple rats, use the multi-mask unit 
1. Check Iso and O2 levels – refill if necessary 
2. Connect filter and O2/Iso 
3. Check water pump level – refill if necessary 
4. Place heating pad over bed 
5. Hook up one warming bed to the water circuit and place it 
under the tail end of the heating pad 
6. Turn on the heating water pump 
7. Position heating lamp over bed and turn on 
a. Note: Be sure not to roast the rats (i.e. not too 
close)! 
ii. If single rat 
1. Same procedure as above except: 
a. Use a single mask 
b. Use two warming beds lined up end-to-end 
iii. For induction chamber 
1. Check Iso and O2 levels – refill if necessary 
2. Make sure the induction chamber bottom is clean – replace 
if necessary 
b. Gather materials for blood collection 
i. Heat Lamp 
ii. BD Microtainer SST REF365967 
1. For collecting blood and separating serum 
iii. Holder for collection tubes 
iv. Kendall Monoject Veterinary I.V. catheters 2419FEP 
1. To stick the ventral artery and guide blood to collection 
tube 
v. Terumo U-100 insulin syringe 3/10cc 29Gx1/2” 
1. To administer acepromazine 
vi. Acepromazine maleate 
1. Vasodilator 
2.  Sedative 
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a. Note: This means the Iso can be turned down from 




ix. Gauze pads 
x. Alcohol and chlorhexiderm soaked gauze for sterilizing the tail 
c. Gather materials for serum storage 
i. Note on centrifuge 
ii. 500uL tubes 
iii. 20uL pipette 
iv. Pipette tips 
v. Holder for tubes 
III. Blood Collection 
a. Transfer rats from rat holding room to procedure room (sign out animals) 
b. Turn on Iso and O2 and turn valve towards the induction chamber 
c. Place rat into induction chamber and wait for it to go under 
d. Turn on Iso and O2 and turn valve towards the mask 
e. Weigh the rat and record value 
f. Move rat over to blood collection station 
g. Ensure the rat is under anesthesia via toe pinch 
h. Calculate amount of Acepromazine needed (weight (kg) X 2.0 1.5 mg/kg 
X concentration of bottle (mL/mg)) 
i. Using insulin syringe, administer needed amount subcutaneously 
i. Record time of injection 
ii. Wait 10 7 full minutes for drug to take effect before collecting 
blood  
j. If necessary, tag the ear 
i. Be sure to decide which ear will be tagged (for multiple groups) 
ii. Tag with number on dorsal side 
iii. Record number 
iv. Write cage number if necessary on cage card and on record sheet 
k. If multiple rats, follow e – j until time to collect blood 
l. Sterilize the rat tail with three passes of alcohol and chlorhexiderm 
m. Take catheter and remove bottom section, leaving the needle and catheter 
only 
n. With non-dominant hand, hold the tail from under the base and trace down 
gently to midpoint 
o. Visually track the artery from the base of the tail to the midpoint 
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p. With the dominant hand, stick the needle at that point at a shallow angle 
along the artery line and insert just over halfway 
i. With older rats, it may be necessary to push through the thicker 
skin at a steeper angle before changing to a shallow angle to 
penetrate the artery 
q. Slowly withdraw the needle+catheter and watch for the flash of blood at 
the bottom 
r. When flash occurs, STOP pulling 
s. Quickly remove the needle, keeping the catheter in place 
t. Grab a collection tube and collect the needed amount of blood 
i. Be sure to place the tube down in a secure place so that no shaking 
and potential hemolysis occurs 
ii. Note: If blood is collected off the tail and not directly into the 
collection tube, the resulting serum samples will be pink (bad) and 
not clear (good). Presumably this is due to hemolysis. 
u. Using the non-dominant hand, immediately apply firm pressure at the 
insertion site and remove the catheter 
v. Wait for adequate hemostasis 
w. Record the time of blood collection 
i. Let blood sit in tubes for at least 1 hour at room temperature to 
allow for adequate clotting 
ii. Label collection tube 
iii. Note: No more than 3 hours from blood collection to serum 
separation (Rat-MID Osteocalcin EIA) 
x. Move rat to recovery warming bed or in cage under heat lamp 
y. When rat has regained consciousness, move it back to its cage and back to 
holding room when ready (sign in animals) 
z. Note: Regularly check Iso and O2 levels 
IV. Serum Separation 
a. Follow the directions provided with the serum separation tubes for proper 
centrifugation (at least 6000g RCF for 2 min. – BD Microtainer SST)  
update to 15,000g RCF for 5 min. 
b. Divide into 40uL aliquots 
c. Be sure to properly label all samples (i.e. rat # and date)!!! 
d. Place in freezer for storage (up to 18 months at -20°C – RatLaps EIA) 
V. Clean up (record time out) 
a. Turn off all Iso, O2, and water pump units 
b. Flush O2 
c. Clean all surfaces with sporacidin 
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d. Remove all induction chamber bottoms to dirty cagewash and replace with 
clean ones 
e. Remove and clean all masks 
f. Return any instruments and materials to original place 




APPENDIX B.  SUPPLEMENTAL DATA 
Table B-1. MicroCT Bone Microarchitecture - HIV-1 tg Male Mouse (FVB/N) 
Skeletal Site Measure WT HIV p-value 
 Body Mass (g) 28.44 ± 0.97 22.56 ± 0.90 < 0.001 
Femur Mid-
diaphysis 
Femur Length (mm) 14.82 ± 0.22 14.19 ± 0.16 0.035 
Ct.Th (μm) 194 ± 9.4 140.4 ± 7.7 < 0.001 
Mineral Density (mg HA/cm3) 1413 ± 28 1425 ± 19 0.727 
MOI (mm4) 0.11 ± 0.01 0.09 ± 0.01 0.081 
pMOI (mm4) 0.30 ± 0.02 0.24 ± 0.01 0.040 
BA (mm2) 0.74 ± 0.04 0.58 ± 0.03 0.003 
TA (mm2) 1.64 ± 0.06 1.61 ± 0.03 0.638 
MA (mm2) 0.90 ± 0.03 1.03 ± 0.03 0.007 
Distal Femur 
Epiphysis 
BV/TV (%) 30.2 ± 1.5 22.7 ± 2.2 0.011 
Conn.D (1/mm3) 375.5 ± 9.8 398.8 ± 25.6 0.405 
SMI 0.68 ± 0.15 1.23 ± 0.26 0.079 
Tb.N (1/mm) 6.64 ± 0.1 6.58 ± 0.07 0.585 
Tb.Th (μm) 48.90 ± 1.57 41.02 ± 2.02 0.007 
Tb.Sp (μm) 148.7 ± 2.7 152.4 ± 2.1 0.295 
Mineral Density (mg HA/cm3) 1117 ± 19 1103 ± 25 0.669 
Distal Femur 
Metaphysis 
BV/TV (%) 13.8 ± 1.1 9.8 ± 1 0.014 
Conn.D (1/mm3) 224.6 ± 23.8 150.2 ± 26 0.049 
SMI 2.38 ± 0.05 2.72 ± 0.12 0.018 
Tb.N (1/mm) 5.74 ± 0.35 5.45 ± 0.16 0.467 
Tb.Th (μm) 39.48 ± 0.86 34.85 ± 1.36 0.035 
Tb.Sp (μm) 181.7 ± 10.8 187 ± 5.3 0.664 
Mineral Density (mg HA/cm3) 1083 ± 23 1090 ± 21 0.823 
Lumbar Spine - L6 
Vertebra 
BV/TV (%) 10.0 ± 0.4 8.0 ± 0.5 0.002 
Conn.D (1/mm3) 44.03 ± 2.27 73.72 ± 8.01 0.006 
SMI -0.25 ± 0.09 0.91 ± 0.2 < 0.001 
Tb.N (1/mm) 1.62 ± 0.12 1.92 ± 0.23 0.245 
Tb.Th (μm) 77.9 ± 1.74 61.29 ± 2.52 < 0.001 
Tb.Sp (μm) 718.0 ± 50.9 647.3 ± 116.3 0.156 
Mineral Density (mg HA/cm3) 1094 ± 4 1023 ± 13 <0.001 
Data are presented as Mean ± SEM. Values in bold indicate significance met at p < 0.05. 
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Table B-2. Bone Biomechanical Properties - HIV-1 tg Male Mouse (FVB/N) 
Bone Measure WT HIV p-value 
Femur Stiffness (N/mm) 64.58 ± 4.78 54.94 ± 4.61 0.165 
Ultimate Load (N) 16.00 ± 0.86 12.84 ± 0.91 0.023 
Displacement at Ultimate Load (mm) 0.42 ± 0.03 0.44 ± 0.03 0.565 
Energy to Ultimate Load (N-mm) 4.36 ± 0.44 3.60 ± 0.39 0.211 
Yield Load (N) 9.34 ± 0.87 7.23 ± 0.66 0.066 
Displacement at Yield Load (mm) 0.16 ± 0.01 0.16 ± 0.02 0.889 
Energy to Yield Load (N-mm) 0.75 ± 0.12 0.54 ± 0.07 0.152 
Failure Load (N) 13.00 ± 1.12 10.90 ± 0.93 0.164 
Displacement at Failure Load (N) 0.67 ± 0.05 0.62 ± 0.07 0.582 
Energy to Failure Load (N-mm) 7.62 ± 0.50 5.42 ± 0.62 0.014 
Postyield Displacement (mm) 0.50 ± 0.05 0.46 ± 0.06 0.61 
Ultimate Stress (MPa) 143.0 ± 7.9 139.7 ± 5.1 0.725 
Elastic Modulus (GPa) 2.84 ± 0.27 3.02 ± 0.21 0.619 
Toughness to Ultimate Stress (MJ/m3) 7.91 ± 0.64 7.71 ± 0.58 0.822 
L6 
Vertebra 
Stiffness (N/mm) 59.75 ± 8.86 41.87 ± 4.82 0.089 
Ultimate Load (N) 20.48 ± 3.49 12.33 ± 0.63 0.021 
Displacement at Ultimate Load (mm) 0.44 ± 0.06 0.39 ± 0.04 0.557 
Energy to Ultimate Load (N-mm) 5.53 ± 1.32 3.12 ± 0.37 0.189 
Yield Load (N) 17.79 ± 3.15 8.58 ± 1.03 0.012 
Ultimate Stress (MPa) 35.96 ± 6.22 34.36 ± 4.48 0.835 
Elastic Modulus (MPa) 208.1 ± 30.9 236.2 ± 45.5 0.629 
Toughness to Ultimate Stress (MJ/m3) 5.01 ± 1.35 4.46 ± 0.83 0.729 
Data are presented as Mean ± SEM. Values in bold indicate significance met at p < 0.05. 
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WT HIV Overall 
p-value 
p-value 
N Mean SEM N Mean SEM 
Max Torque  
(N-mm) 
2 10 23.96 0.88 8 21.67 1.64 
0.060 
0.314 




2 10 10.98 0.75 8 12.38 1.50 
0.030 
0.227 




2 10 2.69 0.21 8 2.34 0.23 
0.128 
0.270 
4 9 2.90 0.21 8 2.31 0.17 0.286 
Energy to Max 
Torque 
(N-mm-deg) 
2 10 151.60 13.68 8 164.26 27.36 
0.890 
0.622 
4 9 176.15 16.71 8 168.55 13.46 0.772 
Data were analyzed using Two-way ANOVA followed by pairwise comparisons using the 
Bonferroni adjustment. (GLM-Univariate, SPSS 24). 
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Table B-4. MicroCT Bone Microarchitecture - FVB/N administered AZT or Water 
Bone Measure AZT Water p-value 
 Body Mass (g) 23.24 ± 0.67 25.39 ± 0.41 0.014 
Femur Mid-
diaphysis 
Femur Length (mm) 14.94 ± 0.10 14.84 ± 0.11 0.542 
Ct.Th (µm) 187.4 ± 5.0 184.2 ± 3.1 1.000 
Mineral Density (mg HA/cm3) 1444 ± 17 1443 ± 16 0.912 
MOI (mm4) 0.106 ± 0.004 0.106 ± 0.003 0.945 
pMOI (mm4) 0.302 ± 0.012 0.280 ± 0.008 0.148 
BA (mm2) 0.73 ± 0.02 0.70 ± 0.01 0.184 
MA (mm2) 0.93 ± 0.02 0.91 ± 0.02 0.296 
TA (mm2) 1.67 ± 0.03 1.61 ± 0.02 0.103 
Femur Distal 
Epiphysis 
BV/TV (%) 29.04 ± 1.07 28.66 ± 1.02 0.739 
Conn.D (mm-3) 342.6 ± 13.9 355.7 ± 15.5 0.537 
SMI 0.69 ± 0.10 0.75 ± 0.09 0.673 
Tb.N (mm-1) 6.31 ± 0.11 6.40 ± 0.14 0.629 
Tb.Th (µm) 49.53 ± 0.47 49.14 ± 0.68 0.644 
Tb.Sp (µm) 155.0 ± 3.1 153.9 ± 4.4 0.848 
Mineral Density (mg HA/cm3) 1150 ± 17 1132 ± 19 0.436 
Femur Distal 
Metaphysis 
BV/TV (%) 12.08 ± 0.84 11.63 ± 0.61 0.669 
Conn.D (mm-3) 186.2 ± 24.0 174.6 ± 15.0 0.686 
SMI 2.37 ± 0.08 2.43 ± 0.06 0.546 
Tb.N (mm-1) 5.28 ± 0.17 5.20 ± 0.11 0.695 
Tb.Th (µm) 40.02 ± 0.42 39.74 ± 0.47 0.661 
Tb.Sp (µm) 193.3 ± 6.9 196.5 ± 4.5 0.703 
Mineral Density (mg HA/cm3) 1112 ± 17 1099 ± 17 0.606 
Lumbar Spine - 
L6 Vertebra 
BV/TV (%) 10.55 ± 0.35 10.00 ± 0.25 0.221 
Conn.D (mm-3) 42.12 ± 2.44 44.59 ± 1.50 0.399 
SMI -0.14 ± 0.07 -0.05 ± 0.08 0.426 
Tb.N (mm-1) 1.85 ± 0.07 1.80 ± 0.09 0.669 
Tb.Th (µm) 78.09 ± 1.02  74.67 ± 0.65 0.011 
Tb.Sp (µm) 578.5 ± 21.3 586.4 ± 42.5 0.869 
Mineral Density (mg HA/cm3) 1106 ± 5 1069 ± 14 0.021 
Data are presented as Mean ± SEM. Values in bold indicate significance met at p < 0.05. 
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Figure B-1. Effect of AZT on biomechanical properties of whole femurs tested in three-
point bending. (A) Measured structural properties. (B) Estimated derived material 






   
   
Figure B-2. Effect of AZT on biomechanical properties of L6 vertebrae tested in 
compression. (A) Measured structural properties. (B) Estimated derived material 





Table B-5. MicroCT Bone Microarchitecture – HIV-1 tg Rat (Male, 14 months old) 
 WT HIV P value 
Femur Mid-diaphysis n = 4 n = 6  
Femur Length (mm) 42.67 ± 0.29 40.73 ± 0.33 0.033 
BV/TV (%) 63.55 ± 0.34 59.78 ± 0.89 0.008 
Ct.Th (mm) 0.62 ± 0.02 0.54 ± 0.02 0.025 
Mineral Density (mg HA/cm3) 1285 ± 18 1326 ± 3 0.110 
MOI (mm4) 11.02 ± 0.80 6.63 ± 0.41 0.008 
pMOI (mm4) 23.82 ± 1.62 13.98 ± 0.86 0.006 
BA (mm2) 8.33 ± 0.32 6.15 ± 0.23 0.003 
MA (mm2) 4.77 ± 0.15 4.13 ± 0.12 0.014 
TA (mm2) 13.10 ± 0.46 10.27 ± 0.30 0.004 
L6 Vertebra n = 5 n = 6  
BV/TV (%) 37.28 ± 0.71 27.13 ± 0.93 0.000 
Tb.N (mm-1) 4.32 ± 0.06 4.08 ± 0.20 0.290 
Tb.Th (µm) 91.80 ± 1.71 74.00 ± 1.53 0.000 
Tb.Sp (µm) 211.0 ± 3.7 238.5 ± 13.8 0.110 
Conn.D (mm-3) 57.52 ± 1.59 82.00 ± 12.30 0.110 
SMI -0.73 ± 0.05 0.12 ± 0.08 < 0.001 
Mineral Density (mg HA/cm3) 1138 ± 12 1158 ± 12 0.280 





   
Figure B-3. Biomechanical properties of bones from HIV-1 tg male rats. (A) Measured 
structural properties of whole femurs tested in 3-point bending. n = 4 WT, n = 6 HIV (B) 
Measured structural properties of L6 vertebrae tested in compression. n = 5 WT, n = 6 HIV. 
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